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Abstract
The Integrated Stress Response (ISR) and the Unfolded Protein Response (UPR) are signaling programs that
enable cellular adaptation to stressful conditions like hypoxia and nutrient deprivation in the tumor
microenvironment. An important effector of these pathways is ATF4, a transcription factor that regulates
genes involved in redox homeostasis, amino acid metabolism and transport, autophagy, and angiogenesis.
However, prolonged activation of the UPR/ISR and resultant ATF4 expression can be cytotoxic under certain
conditions. In these studies, we characterized a small molecule compound, E235, which activated the ISR and
dose-dependently increased levels of ATF4 in transformed cells. A dose-dependent decrease in viability was
observed in several mouse and human tumor cell lines, and knockdown of ATF4 significantly increased the
anti-proliferative effects of E235. Interestingly, low μM doses of E235 induced senescence in many cell types.
E235-mediated induction of senescence was not dependent on p21 or p53; however, p21 conferred
protection against the growth inhibitory effects of E235. Treatment with E235 resulted in an increase in cells
arrested at the G2/M phase. E235 also activated DNA damage response signaling, although E235 did not
appear to cause physical DNA damage. Induction of γ-H2AX was abrogated in ATF4 knockdown cells.
Together, these results suggest that modulation of the ISR pathway with the small molecule E235 could be a
promising anti-tumor strategy.
We also investigated the potential role of ATF4 in tumor metastasis. Constitutive knockdown of ATF4
expression in HT1080 fibrosarcoma cells completely prevented the lung colonization of these cells when
injected intravenously in mice. This phenomenon may be tumor type specific however, as ATF4 ablation in
mouse mammary carcinoma cells had no effect on the ability of these cells to colonize various organs of the
mice. In addition, we generated HT1080 cells with an inducible knockdown of ATF4 and demonstrated an
increased tumor growth rate upon downregulation of ATF4 expression. However, ATF4 knockdown did not
affect the migration of HT1080 cells. This, together with results from a colleague showing that ATF4 protects
cells from anoikis, led us to propose that ATF4 may be facilitating metastasis by protecting tumor cells during
detachment and circulation.
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ABSTRACT 
 
THE INTEGRATED STRESS RESPONSE EFFECTOR ATF4: 
CHARACTERIZATION OF A SMALL MOLECULE MODULATOR OF ITS 
EXPRESSION AND INVESTIGATION OF THE ROLE OF ATF4 IN 
METASTASIS 
Carly M. Sayers 
Constantinos Koumenis 
 
The Integrated Stress Response (ISR) and the Unfolded Protein Response (UPR) are 
signaling programs that enable cellular adaptation to stressful conditions like hypoxia 
and nutrient deprivation in the tumor microenvironment. An important effector of these 
pathways is ATF4, a transcription factor that regulates genes involved in redox 
homeostasis, amino acid metabolism and transport, autophagy, and angiogenesis. 
However, prolonged activation of the UPR/ISR and resultant ATF4 expression can be 
cytotoxic under certain conditions. In these studies, we characterized a small molecule 
compound, E235, which activated the ISR and dose-dependently increased levels of 
ATF4 in transformed cells. A dose-dependent decrease in viability was observed in 
several mouse and human tumor cell lines, and knockdown of ATF4 significantly 
increased the anti-proliferative effects of E235. Interestingly, low µM doses of E235 
induced senescence in many cell types. E235-mediated induction of senescence was 
not dependent on p21 or p53; however, p21 conferred protection against the growth 
inhibitory effects of E235. Treatment with E235 resulted in an increase in cells arrested 
at the G2/M phase. E235 also activated DNA damage response signaling, although 
E235 did not appear to cause physical DNA damage. Induction of γ-H2AX was 
v 
 
abrogated in ATF4 knockdown cells. Together, these results suggest that modulation of 
the ISR pathway with the small molecule E235 could be a promising anti-tumor strategy. 
 
We also investigated the potential role of ATF4 in tumor metastasis. Constitutive 
knockdown of ATF4 expression in HT1080 fibrosarcoma cells completely prevented the 
lung colonization of these cells when injected intravenously in mice. This phenomenon 
may be tumor type specific however, as ATF4 ablation in mouse mammary carcinoma 
cells had no effect on the ability of these cells to colonize various organs of the mice. In 
addition, we generated HT1080 cells with an inducible knockdown of ATF4 and 
demonstrated an increased tumor growth rate upon downregulation of ATF4 expression. 
However, ATF4 knockdown did not affect the migration of HT1080 cells. This, together 
with results from a colleague showing that ATF4 protects cells from anoikis, led us to 
propose that ATF4 may be facilitating metastasis by protecting tumor cells during 
detachment and circulation.  
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Chapter I: Introduction 
 
The tumor microenvironment is a complex system containing fibroblasts, blood vessels, 
extracellular matrix, immune cells, cytokines and other signaling molecules, in addition to 
the tumor cells themselves (McAllister & Weinberg, 2010). Conditions in the tumor 
microenvironment are harsh compared to normal tissue: tumor cells are frequently 
subjected to low oxygen availability (hypoxia), decreased levels of essential nutrients, 
and low pH (Lunt et al, 2009). In order to survive, the tumor cells must adapt to these 
stresses. However, many of the same mechanisms that the cells engage for survival can 
also enhance tumor progression and metastasis (Fels & Koumenis, 2006; Nagasawa, 
2011; Wouters & Koritzinsky, 2008). One critical protein employed by tumor cells to 
ameliorate stress from the microenvironment is the transcription factor ATF4 (activating 
transcription factor 4) (Harding et al, 2003). In this work, efforts to characterize a small 
molecule modulator of ATF4 expression, as well as the role of ATF4 in tumor cell 
metastasis, will be described.  
 
The tumor microenvironment: hypoxia 
A common characteristic of most solid tumors is the presence of hypoxic regions, where 
the oxygen concentration can be as low as 0.01%, while oxygen levels in normal tissue 
range from 3.1-8.7% (Höckel & Vaupel, 2001b). Chronic hypoxia occurs when the tumor 
outgrows the existing vasculature, increasing the distance oxygen must diffuse to reach 
portions of the tumor. Tumors can also experience acute, or intermittent, hypoxia, which 
is caused by abnormal blood flow dynamics in the newly forming vessels (Kizaka-
Kondoh et al, 2003). Tumor cells can survive adverse hypoxic conditions for extended 
periods of time depending on factors such as expression of anti-apoptotic genes, 
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mutations in proapoptotic genes and activation of pro-survival programs. Clinically, 
hypoxic tumors are more resistant to both chemotherapy, due to limited drug diffusion 
and cell cycle dysregulation, and radiation therapy, due to reduced levels of DNA 
damage (Brown & Wilson, 2004). Moreover, the metastatic potential of cancer cells has 
been shown to be increased by hypoxia (Brizel et al, 1996; Brown, 1990; Cairns & Hill, 
2004; Chang et al, 2011). It is not surprising then that hypoxia has been associated with 
poor local tumor control and reduced overall survival (Brizel et al, 1996; Höckel et al, 
1993; Höckel & Vaupel, 2001a; Koumenis, 2006; Vaupel et al, 2001).  
 
Cells adapt to hypoxic stress using HIF (hypoxia-inducible factor)-dependent and HIF-
independent pathways (Bertout et al, 2008; Koumenis, 2006; Semenza, 2009). The HIF-
dependent pathway regulates the expression of proteins important for anaerobic 
glycolysis, angiogenesis, and cell survival (Bertout et al, 2008; Semenza, 2009). HIF-
independent effects are designed to curtail oxygen consumption by energy expensive 
processes, such as DNA replication and protein synthesis (Koumenis, 2006).  
 
The tumor microenvironment: nutrient deprivation 
Another consequence of poor tumor vascularization is a reduced supply of essential 
nutrients, including glucose and amino acids (Folkman, 1971). Compounding this is the 
fact that tumor cells have a much higher demand for nutrients than normal cells, due to 
their uncontrolled proliferation (Andreeff et al, 2000). Cellular proliferation is an energy 
intensive process, and tumor cells rely heavily on glucose uptake and glycolysis to 
provide this energy (Gatenby & Gillies, 2004). Another nutrient that is essential for tumor 
cell survival is glutamine, which cells use for both energy production and as a source of 
carbon during amino acid and lipid synthesis (Coles & Johnstone, 1962; DeBerardinis et 
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al, 2007). Because the rapid proliferation of tumor cells requires high levels of protein, 
DNA and lipid synthesis, stores of nutrients, like glucose, glutamine and other amino 
acids, can be depleted (Romero-Garcia et al, 2011). Consequently, cancer cells typically 
employ mechanisms, such as the unfolded protein response (UPR) and the integrated 
stress response (ISR), to survive these harsh microenvironmental conditions. 
 
The unfolded protein response 
The UPR is a HIF-independent coordinated cellular program induced by cells to adapt to 
transient and chronic endoplasmic reticulum (ER) stress caused by factors such as 
unfolded proteins, hypoxia, nutrient deprivation, and oncogenic transformation 
(Kaufman, 2002; Schönthal, 2012). Induction of the UPR relies on three ER 
transmembrane proteins: PKR-like endoplasmic reticulum kinase (PERK), inositol-
requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) (Fig.1). During 
unstressed conditions, these signaling transducers are maintained in an inactive state by 
an ER lumenal chaperone protein called GRP78 (glucose-regulated protein, 78kDa; also 
known as BiP). When misfolded proteins begin to accumulate, GRP78 dissociates from 
PERK, IRE1 and ATF6 to aid in protein folding and degradation, which allows the 
activation of these three proteins (Bertolotti et al, 2000; Shen et al, 2002).  
 
Activation of PERK involves homodimerization and autophosphorylation (Bertolotti et al, 
2000). One major target of PERK is eukaryotic initiation factor 2 α-subunit (eIF2α) 
(Harding et al, 2000b; Harding et al, 1999). Normally, eIF2α binds GTP as part of the 
initiation of cap-dependent translation. To begin the elongation phase of translation, 
eIF2α-GTP is hydrolyzed to eIF2α-GDP, which then disassociates from the ribosome.  
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Fig. 1. The Unfolded Protein Response. UPR initiation involves three ER-resident 
proteins: PERK, IRE1, and ATF6. Upon activation, these signal transducers induce 
separate, yet sometimes overlapping, gene transcription programs. 
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When PERK phosphorylates eIF2α at serine 51, the exchange of GDP for GTP is 
inhibited. This leads to a global reduction in translation, preventing further accumulation 
of unfolded proteins in the ER. Paradoxically, translation of a few mRNAs is substantially 
elevated under these conditions. The most extensively studied of these mRNAs is that 
encoding ATF4 (activating transcription factor 4) (Harding et al, 2000a; Shi et al, 1998; 
Vattem & Wek, 2004). ATF4 is involved in the transcription of genes encoding proteins 
that assist the cell in neutralizing the stress, such as chaperones and proteins important 
for amino acid metabolism, redox homeostasis, angiogenesis, and autophagy (Avivar-
Valderas et al, 2011; Dickhout et al, 2012; Harding et al, 2003; He et al, 2001; Pereira et 
al, 2010; Pike et al, 2013; Rouschop et al, 2010; Rzymski et al, 2010). ATF4 also 
upregulates the transcription of CHOP (C/EBP homologous protein), a pro-apoptotic 
protein that will be discussed in more detail later (Friedman, 1996; Harding et al, 2000a).  
 
The second branch of the UPR is mediated by IRE1. Like PERK, dissociation of GRP78 
allows IRE1 homodimerization and autophosphorylation (Bertolotti et al, 2000). Activated 
IRE1 also possesses endonuclease activity, which processes unspliced XBP1 mRNA by 
removing an inhibitory intron (Tirasophon et al, 1998; Yoshida et al, 2001). The spliced 
mRNA can then be translated to the functional XBP1-s protein, a transcription factor 
important for the upregulation of genes involved in protein folding and disulfide bond 
formation and ER-associated protein degradation (Calfon et al, 2002; Lee et al, 2003a; 
Yamamoto et al, 2004; Yoshida et al, 2001).  
 
ATF6 regulates the third branch of the UPR. Unlike PERK and IRE1, when ATF6 is 
released from GRP78 binding, it translocates to the Golgi apparatus (Chen et al, 2002). 
Once in the Golgi, two resident proteases cleave ATF6 to release the cytosolic 
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transcription factor domain (Ye et al, 2000). This activated ATF6 domain then 
translocates to the nucleus, where it stimulates the transcription of XBP1 and genes 
encoding protein chaperones (Haze et al, 1999; Okada et al, 2002; Yoshida et al, 2001). 
 
The integrated stress response 
Another coordinated program activated by microenvironmental stresses, including 
nutrient deprivation, ER stress, and hypoxia, is called the ISR (Harding et al, 2003; 
Koumenis et al, 2002). The ISR is a cellular pathway designed to curtail global 
translation, and it is characterized by the phosphorylation of eIF2α at Ser51 and 
subsequent translation of ATF4 (Harding et al, 2003). PERK, as well as three other 
known kinases – GCN2 (general control non-derepressible 2), PKR (double stranded 
RNA activated protein kinase) and HRI (heme-regulated inhibitor kinase) – are 
responsible for initiating the ISR (Fig. 2). Each kinase responds to different stressors. 
For instance, low levels of amino acids initiate the ISR via GCN2 (Berlanga et al, 1999; 
Harding et al, 2000a). When amino acids are depleted, uncharged tRNA levels increase. 
GCN2 is activated by binding to these uncharged tRNAs (Wek et al, 1995). HRI is mainly 
expressed in erythrocytes and is activated by heme deficiency, while PKR is ubiquitously 
expressed and plays an important role in antiviral immunity by responding to double-
stranded RNA (Ranu & London, 1976; Thomis & Samuel, 1992). Upon activation, all four 
kinases phosphorylate eIF2α, leading to general inhibition of protein translation and 
paradoxical upregulation of ATF4 as discussed above.  
 
Physiological and pharmacological activation of the UPR and ISR 
There are numerous physiological conditions that can activate the UPR and ISR, some 
of which have already been mentioned. Excessive quantities of unfolded or misfolded  
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Fig. 2. The Integrated Stress Response. Four kinases, PERK, GCN2, PKR and HRI, 
mediate the ISR, which involves general translation inhibition and upregulation of ATF4 
via phosphorylation of eIF2α. 
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proteins, hallmarks of several pathological conditions including neurodegenerative 
diseases, diabetes and cancer, cause ER stress (Xu et al, 2005). Hypoxia also 
stimulates the UPR by disrupting proper protein disulfide bridge formation (Tu & 
Weissman, 2004). Specifically, protein disulfide isomerase (PDI) oxidizes disulfide bonds 
and is activated by a chain of redox reactions that requires molecular oxygen as the final 
electron acceptor. During hypoxic conditions, PDI activity is impaired, causing an 
increase in unfolded proteins by reducing the formation of protein disulfide bonds. 
Another stimulus is amino acid deprivation, which activates GCN2 and the ISR by the 
mechanism mentioned above (Wek et al, 1995). Low levels of glucose, on the other 
hand, trigger both the UPR and the ISR via PERK and GCN2 (Muaddi et al, 2010). The 
ER is responsible for glycosylating certain proteins, a process that is dependent on 
glucose. When glucose is scarce, glycosylation is reduced, and the un-glycosylated 
proteins are retained in the ER, increasing the ER protein load and activating the UPR 
(Fernandez et al, 2002; Lee, 2001). In addition, cells will use amino acids as a source of 
energy when glucose is unavailable, leading to amino acid deprivation and GCN2/ISR 
activation (Yang et al, 2000; Ye et al, 2010). Another common occurrence in tumors is 
the expression of oncogenes. Oncogenes can invoke UPR signaling indirectly by 
promoting cell proliferation and subsequent protein synthesis, increasing the ER client 
protein load (Denoyelle et al, 2006; Hart et al, 2012). 
 
Various pharmacological agents exist that are useful for studying the mechanisms and 
consequences of UPR signaling. One example is thapsigargin, a potent inducer of the 
UPR. Thapsigargin inhibits SERCA (sarcoplasmic/endoplasmic reticulum calcium 
ATPase) pumps, which are responsible for preserving ER calcium homeostasis 
(Gunteski-Hamblin et al, 1988; Lytton et al, 1991). Since ER-resident protein folding 
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chaperones are dependent upon calcium for their chaperone activity, this perturbation 
increases the level of unfolded proteins (Kassenbrock & Kelly, 1989). Another UPR 
activator is tunicamycin, an inhibitor of N-linked glycosylation, which stimulates UPR 
signaling by causing the retention of un-glycosylated proteins in the ER in a manner 
similar to glucose deprivation (Elbein, 1987; Kuo & Lampen, 1974). Additionally, 
proteasome inhibitors, such as bortezomib, cause UPR activation by preventing the 
degradation of misfolded proteins and have proven to be clinically useful cancer 
treatments (Lee et al, 2003b; Schönthal, 2012). 
 
Regulation of ATF4 expression 
As mentioned earlier, the major mechanism controlling the expression of ATF4 occurs at 
the translational level (Harding et al, 2000a). The 5’ untranslated region of the ATF4 
mRNA contains two upstream open reading frames, or uORFs, that are essential for the 
differential translation of ATF4 (Lu et al, 2004; Vattem & Wek, 2004). The first, uORF1, 
encodes a three amino acid polypeptide and facilitates ribosome scanning and 
translation reinitiation. The second, uORF2, overlaps with the beginning of the ATF4 
coding region, but only by 83 nucleotides. During unstressed conditions, when there are 
high levels of eIF2α bound to GTP, uORF1 is translated and then ribosomes reinitiate at 
the next downstream coding region, uORF2. When uORF2 is translated, the start codon 
of ATF4 is bypassed, and the translation of functional ATF4 protein is repressed. 
However, when cells are stressed, eIF2α-GTP quantities are depleted, increasing the 
time needed to reinitiate translation. This delay causes the scanning ribosomes to 
bypass translation at uORF2 and, instead, to reinitiate translation at the start of the 
coding region, effectively inducing ATF4 protein expression (Lu et al, 2004; Vattem & 
Wek, 2004).  
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ATF4 expression can also be controlled transcriptionally and post-translationally. 
Several studies have reported an increase in ATF4 mRNA levels in response to ER 
stress, viral infection and nutrient deprivation (Caselli et al, 2012; Dey et al, 2010; Siu et 
al, 2002). In contrast, hypoxia does not change the amount of ATF4 mRNA, while UV 
radiation actually inhibits the transcription of ATF4 (Blais et al, 2004; Dey et al, 2010). 
Like ATF4 transcription, the stability of the ATF4 protein can be both positively and 
negatively modulated. ATF4 contains a recognition motif for βTrCP (beta-transducin 
repeat containing E3 ubiquitin protein ligase), and phosphorylation of the serine within 
this domain results in ubiquitination by the Skp1-Cul1-F-boxβTrCP complex and 
subsequent proteasomal degradation (Lassot et al, 2001). The histone acetyltransferase 
p300 stabilizes ATF4 by preventing the binding of βTrCP; however, this is independent 
of the acetylation activity of p300 (Lassot et al, 2005). 
 
ATF4 
A member of the activating transcription factor/cAMP responsive element binding protein 
family, ATF4 is a basic-region leucine zipper transcription factor that recognizes cAMP 
responsive elements (CRE) within gene promoters (Ameri & Harris, 2008). ATF4 can 
either activate or repress the transcription of its target genes, and its specific pattern of 
gene expression depends on its dimerization partner (Ameri & Harris, 2008). Many of the 
key targets of ATF4 are genes encoding proteins that assist in mitigating the ISR-
activating cellular stresses. For example, ATF4 upregulates expression of protein 
chaperones (GRP78) and proteins involved in amino acid transport and synthesis 
(asparagine synthetase, glycine transporter 1, and several tRNA synthetases) and redox 
homeostasis (cystathionine γ-lyase and heme oxygenase 1) (Dickhout et al, 2012; 
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Harding et al, 2003; He et al, 2001). Other targets of ATF4 include genes important for 
autophagy (unc-51-like kinase 1 (ULK1), beclin 1, microtubule-associated protein 1 light 
chain 3 beta (LC3B)), a process that assists cells in replenishing nutrients by degrading 
cellular organelles (Avivar-Valderas et al, 2011; Pike et al, 2013; Rouschop et al, 2010; 
Rzymski et al, 2010). Still others help to alleviate hypoxia and nutrient deprivation by 
increasing blood supply by promoting angiogenesis (vascular endothelial growth factor 
A, angiogenin, fibroblast growth factor 2) (Pereira et al, 2010). ATF4 also activates its 
own regulatory feedback loop by inducing GADD34 (growth arrest and DNA damage-
inducible protein 34) transcription (Ma & Hendershot, 2003). GADD34 is a component of 
the phosphatase complex that dephosphorylates eIF2α, thus ensuring that the activation 
of the ISR and subsequent inhibition of protein synthesis are only transient (Novoa et al, 
2001). In addition, ATF4 upregulates transcription factors such as ATF3 (activating 
transcription factor 3) and CHOP (Harding et al, 2000a; Jiang et al, 2004). CHOP (also 
called GADD153) is thought to promote ER stress-induced apoptosis by repressing the 
transcription of anti-apoptotic BCL2 (B-cell CLL/lymphoma 2) while upregulating pro-
apoptotic BIM (BCL2-like 11 (apoptosis facilitator)) (Matsumoto et al, 1996; McCullough 
et al, 2001; Puthalakath et al, 2007). ATF3 plays an important role in controlling innate 
immunity by repressing the transcription of various cytokines (Thompson et al, 2009). It 
has also been reported to have opposing effects on tumorigenesis: ATF3 increases the 
invasive and metastatic potential of cancer cells but reduces primary tumor growth 
(Thompson et al, 2009).  
 
ATF4 also regulates the expression of genes during development. Global deletion of the 
Atf4 gene in mice is not embryonically lethal; however, Atf4-/- mice are anemic and 
exhibit abnormal lens formation and reduced overall growth (Masuoka & Townes, 2002; 
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Tanaka et al, 1998). These phenotypic abnormalities were attributed to a defect in cell 
proliferation, as Atf4-/- embryonic fibroblasts had a reduced rate of proliferation (Masuoka 
& Townes, 2002). Additionally, ATF4 is essential for normal bone formation and 
osteoblast differentiation and function (Yang et al, 2004). A recent report demonstrating 
a role for ATF4 in the EMT of neural crest cells during embryogenesis further illustrates 
the importance of ATF4 for normal development and suggests an alternate explanation 
for the phenotypic abnormalities seen in Atf4-/- mice (Suzuki et al, 2010).  
 
It has been demonstrated by our lab and others that ATF4 plays an important role in 
tumor growth and in tumor cell survival. Atf4-/- transformed mouse fibroblasts (MFs) 
displayed higher levels of apoptosis when exposed to moderate to extreme hypoxia (1% 
to <0.02% O2), while HT1080 human fibrosarcoma cells that were transfected with 
shRNA against ATF4 (shATF4) showed reduced cell proliferation and increased 
apoptosis when not supplemented with nonessential amino acids (Bi et al, 2005; Harding 
et al, 2003; Ye et al, 2010). When HT1080 shATF4 cells were implanted subcutaneously 
in nude mice, the resultant tumors were smaller and had a lower cell proliferation index 
than tumors formed from HT1080 cells transfected with nontargeting shRNA (Ye et al, 
2010). Importantly, a physiologically relevant role for ATF4 was confirmed, as human 
glioblastomas, breast adenomas, cervical carcinomas, and melanomas exhibit 
overexpression of ATF4 compared to corresponding normal tissue (Bi et al, 2005). In 
addition, ATF4 expression was shown to overlap with areas of hypoxia in human cervical 
carcinomas (Bi et al, 2005). Interestingly, ATF4 overexpression correlates with 
resistance to numerous chemotherapeutic drugs, including cisplatin, doxorubicin, 
vincristine, and etoposide (Igarashi et al, 2007; Tanabe et al, 2003). Together, these 
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results suggest that ATF4 is important for cancer cell survival within the hypoxic, 
nutrient-deprived tumor microenvironment.  
 
Life and death balance by the UPR and ISR 
Despite an initial induction of cytoprotective programs during cellular stress, prolonged 
or chronic activation of the UPR and ISR can lead to cell death (Fig. 3). ATF4 
upregulates the transcription of CHOP, which, as mentioned above, promotes apoptosis 
by repressing the transcription of BCL2 and upregulating BIM (McCullough et al, 2001; 
Puthalakath et al, 2007). Another method by which CHOP may induce apoptosis is by 
hyperoxidation of the ER lumen by the CHOP transcription target ERO1α (ER 
oxidoreductase 1α), leading to calcium leakage from the ER into the cytosol and 
subsequent activation of CaMKII (calcium/calmodulin-dependent protein kinase II) and 
its pro-apoptotic functions (Tabas & Ron, 2011). Overexpression of GADD34 by both 
ATF4 and CHOP is thought to induce apoptosis by premature dephosphorylation of 
eIF2α and reinitiation of global translation, potentially leading to ER overload (Koumenis, 
2006). On the other hand, if the UPR and/or ISR are overactivated, prolonged inhibition 
of protein synthesis via persistent eIF2α phosphorylation could cause cell growth arrest 
or cell death (Koumenis, 2006). Providing evidence to support this are studies showing 
that combining two UPR/ISR inducers, such as hypoxia and thapsigargin or hypoxia and 
bortezomib, results in enhanced tumor cell death (Fels et al, 2008; Obeng et al, 2006).  
 
Cellular senescence 
Cytotoxicity via apoptosis is only one of several ways in which cancer therapies impart 
tumor control. A cessation of cell division by cytotoxic or cytostatic insults, called  
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Fig. 3. The UPR and ISR: balance between life and death. The UPR and ISR initially 
activate cytoprotective signaling cascades, but prolonged or excessive stresses can shift 
the balance toward the cytotoxic effects of these pathways. 
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clonogenic cell death, means that a tumor cell is no longer capable of multiplying. In 
addition to apoptosis, cancer treatments can induce clonogenic cell death by necrosis, 
mitotic catastrophe, or senescence. Cellular senescence is defined as an essentially 
irreversible growth arrest, where the cell remains metabolically active but is unable to 
divide (Hayflick, 1965; Hayflick & Moorhead, 1961). Senescence can be induced in vitro 
and in vivo by telomere shortening, oxidative stress, DNA damage and oncogene 
activation (Fig. 4) (Ewald et al, 2010; Kuilman et al, 2010). It has been shown to be a key 
barrier to the development of tumors in vivo, although senescent cells can also promote 
tumor progression by providing pro-tumorigenic signals to neighboring cells (Braig et al, 
2005; Rodier & Campisi, 2011). Two common mediators of senescence activation are 
the p53 and p16-RB1 (retinoblastoma 1) pathways. However, cells without functional 
p53 can still undergo senescence, indicating that there are additional mechanisms for 
inducing cellular senescence, such as overexpression of p21 (Chan et al, 2011; Fang et 
al, 1999).  
 
While there is no single marker for identifying senescent cells, there are several key 
characteristics typically – but not always – displayed during senescence (Ewald et al, 
2010; Kuilman et al, 2010). Cells exhibit morphological changes when they senesce, 
becoming larger but flatter with multiple nuclei. Senescent cells also undergo cell cycle 
arrest at either the G1/S or G2/M stage (Bringold & Serrano, 2000). This is usually 
accompanied by an increase in expression of one or more cyclin-dependent kinase 
inhibitors, such as p16, p21, and p27 (Bringold & Serrano, 2000; Ewald et al, 2010; 
Kuilman et al, 2010). Other senescence markers include the induction of senescence-
associated β-galactosidase (SA-β-gal) activity, which is partially due to an increase in 
lysosomal mass, and the formation of senescence-associated heterochromatin foci  
16 
 
 
 
Fig. 4. Causes and characteristics of cellular senescence. Cellular senescence can 
be triggered by a variety of factors, including telomere shortening, oncogene activation, 
DNA damage, and ROS. While no one assay exists for identifying senescent cells, 
several different markers can be used to classify a cell as senescent, such as β-
galactosidase activity, DNA damage signaling, and other typical characteristics.  
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(Dimri et al, 1995; Narita et al, 2003). In addition, senescent cells sometimes display 
persistent DNA damage response signaling (DDR), characterized by ATM (ataxia 
telangiectasia mutated) activation, phosphorylation of serine 15 on p53, phosphorylation 
and activation of Chk1 and Chk2 (checkpoint kinase 1 and 2), and/or H2A histone family, 
member X phosphorylation (γ-H2AX) (d'Adda di Fagagna et al, 2003).  
 
ATF4 and senescence 
There have been conflicting reports on the impact of ATF4 expression during 
senescence. For example, an early study showed that expression of H-Ras induced 
cellular senescence driven by UPR signaling (Denoyelle et al, 2006). Specifically, the 
authors showed that H-Ras transduction stimulated ATF4 protein expression and that 
knocking down ATF4 substantially decreased the number of SA-β-gal positive cells. 
Supporting this was a more recent investigation that demonstrated that ATF4 
knockdown in MEFs with heterozygous deletion of the tumor suppressor Pten 
(phosphatase and tensin homolog) and homozygous deletion of the ubiquitin ligase 
Skp2 (S-phase kinase-associated protein 2) resulted in a reduction of senescent cells 
(Lin et al, 2010). While these studies support a role for ATF4 in the induction of 
senescence, others have found that, instead, ATF4 prevents cellular senescence. One 
group recently published data showing that ablation of ATF4 in H-Ras-transformed MEF 
xenografts caused a significant increase in the percentage of SA-β-gal positive cells 
(Horiguchi et al, 2011). Further research will be necessary to elucidate the exact function 
of ATF4 in the onset and maintenance of cellular senescence.  
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Metastasis 
Metastasis is defined as the dissemination and colonization of cancer cells from the 
primary tumor to distant sites. It is typically considered to consist of five steps, including 
invasion and migration, intravasation, circulation, extravasation, and colonization and 
proliferation in a secondary location (Fig. 5) (Leber & Efferth, 2009; Valastyan & 
Weinberg, 2011). Invasion and migration refers to the ability of cells to detach from the 
primary tumor and invade surrounding tissues (Yilmaz & Christofori, 2009). It is thought 
that, in epithelial tumors, EMT may play a key part in this step, as EMT is characterized 
by the dissolution of cell-cell junctions and increased motility of the cells (Bonnomet et 
al, 2010; Valastyan & Weinberg, 2011). Next, the cells intravasate, or invade and enter, 
into the blood and lymphatic vessels. The cancer cells must then survive the hostile 
environment of the circulation and resist anoikis, which is cell death caused by loss of 
contact with the extracellular matrix (ECM) (Frisch & Francis, 1994; Kim et al, 2012). 
Then, usually once the cells arrest in the capillaries of an organ, the cells extravasate 
and exit the vessel. The final step in metastasis involves the survival of the cell in the 
new site and its subsequent ability to proliferate and induce angiogenesis (Valastyan & 
Weinberg, 2011). The reversion of EMT, or MET, may be important for this last step 
(Brabletz et al, 2005; Tsai et al, 2012).  
 
ATF4 and metastasis 
Recently, it was shown that deletion of PERK in a mouse model of mammary carcinoma 
significantly reduced the incidence of tumor metastasis (Bobrovnikova-Marjon et al, 
2010). Since ATF4 is downstream of PERK, it could also play a role in the metastatic 
cascade. Indeed, several studies provide evidence that ATF4 may contribute to tumor  
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Fig. 5. The metastatic cascade. Metastasis is comprised of five different steps: 
invasion and migration, intravasation, circulation, extravasation, and colonization and 
proliferation.  
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cell migration and invasion. For instance, ATF4, via hypoxic activation of PERK, has 
been implicated in the upregulation of lysosomal-associated membrane protein 3 
(LAMP3), a protein shown to induce metastasis of subcutaneous tumor xenografts 
(Kanao et al, 2005; Mujcic et al, 2009). Furthermore, knockdown of ATF4 decreased the 
migration of breast cancer cells in in vitro assays (Nagelkerke et al, 2013). Additionally, it 
has been reported that ATF4 is a crucial regulator of EMT in avian neural crest cells, 
providing more evidence that ATF4 may play a role in promoting the migration and 
invasion stage of metastasis (Suzuki et al, 2010). 
 
Another possible step where ATF4 could be supporting metastasis is by enabling the 
cancer cells to resist anoikis in the bloodstream. Cells that detach from the ECM 
experience a decrease in glucose intake and energy levels with a concomitant increase 
in ROS (Schafer et al, 2009). Autophagy, a process in which cells engulf their organelles 
in vesicles for lysosomal degradation, allows the cells to adapt to the reduced ATP levels 
by recycling cellular components to use as sources of energy (Fung et al, 2008; Kim et 
al, 2012). Because ATF4 mediates a transcriptional program designed to both induce 
autophagy and mitigate cellular stresses like increased ROS, it is reasonable to posit 
that ATF4 may protect circulating tumor cells from anoikis. Supporting this is a study that 
demonstrated that ATF4 was essential for the induction of autophagy and subsequent 
survival of ECM-detached mammary epithelial cells (Avivar-Valderas et al, 2011). 
Another group showed that expression of ATF4 was higher in circulating tumor cells than 
in the primary orthotopic tumor, suggesting that detachment of the cells corresponds to 
an induction of ATF4 expression (Ameri et al, 2010).  
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Project aims 
Based on the prior observations that prolonged or overactivation of the ISR and UPR 
can lead to cell death, one aim of this research project was to characterize a small 
molecule compound, called E235, that activated the ISR and induced the translation of 
ATF4. We demonstrated that E235 possesses potent anti-proliferative activity against 
many transformed cells.  Interestingly, E235 failed to upregulate ATF4 activity in normal, 
untransformed human diploid fibroblasts.  Further analysis revealed that E235 causes 
cellular senescence in a p53- and p21-independent manner, as well as a G2/M cell cycle 
arrest, also in a p21-independent manner. Knockdown of ATF4 did not substantially 
affect senescence, but it increased overall cytotoxicity induced by E235. A detailed 
description of these effects can be found in Chapter II. 
 
Previously it was shown that knockdown of one of the ISR kinases, PERK, reduces the 
incidence of metastasis (Bobrovnikova-Marjon et al, 2010). In addition, ATF4 has been 
implicated in the transcription of a gene associated with metastasis, LAMP3 (Mujcic et 
al, 2009). Therefore, we reasoned that expression of ATF4 facilitates the metastasis of 
tumor cells, so the second goal of this project was to investigate this possibility. We 
found that ATF4 expression had no bearing on the migratory capacity of human 
fibrosarcoma cells. Also, ablation of ATF4 expression did not affect the ability of mouse 
mammary carcinoma to colonize in various organs of mice. However, we did establish 
that knockdown of ATF4 in the fibrosarcoma line completely abolished murine lung 
colonization. Chapter III contains a complete report of these results.  
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Chapter II: Identification and characterization of a potent 
activator of p53-independent cellular senescence via a small 
molecule screen for modifiers of the Integrated Stress Response 
effector ATF4 (Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics) 
 
In this chapter, the characterization of E235, a senescence-inducing modulator of ATF4 
expression, will be described. The majority of this work was recently published in 
Molecular Pharmacology (Sayers et al, 2012). Reprinted with permission of the 
American Society for Pharmacology and Experimental Therapeutics. All rights reserved. 
 
A. Results 
Identification of E235 as a modulator of ATF4 response. The ATF4 gene product is a 
crucial mediator of the response to both ER stress and nutrient deprivation in cells. It has 
been demonstrated that fusion of the ATF4 5’-UTR to luciferase (Fig. 6A) confers 
substantial upregulation of luciferase expression when cells are exposed to 
pharmacological activators of the UPR (e.g., Thapsigargin or tunicamycin) (Vattem & 
Wek, 2004). For screening of small molecule libraries, we used HT1080 cells stably 
expressing the ATF4 5’UTR-luciferase construct for the primary screens.  The chemical 
library at Stanford University represents an expanded diverse small molecule library with 
compounds obtained from Specs, Chembridge, ChemRX and Chemdiv.  Compounds 
with Z factor scores of >0.5 were further evaluated in an expanded secondary screen, 
utilizing HT1080 cells expressing CMV-luciferase, XBP1-luciferase, and ATF4 5’UTR-
luciferase.  In the secondary screen, we assessed the ATF4-Luc modifying activity of 
each screening hit over a concentration range of up to 3 logs.  Compounds that  
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Fig. 6. Treatment with E235 increases ATF4 expression. A) Schematic of the ATF4-
luciferase reporter construct used in the chemical library screen. B) Chemical structure 
of E235. C) Induction of ATF4 translation was analyzed by measuring luciferase activity 
in HT1080 cells transfected with ATF4-Luc. Luciferase activity was measured at 0, 4, 
and 8 hours after treatment with 1 or 10µM E235. Fold change was determined by 
dividing the ATF4-Luc signal by the signal from a constitutively active reporter plasmid 
(CMV-Luc). *p<0.05 or ***p<0.001 as compared to DMSO-treated controls (student’s t-
test; n=3). D-F) ATF4 protein expression in HT1080 (D), B16F10 (E), and AG1522 (F) 
cells was examined by immunoblotting after 4 hours of treatment with 0, 1, 5, or 10µM 
E235. Thapsigargin treatment (0.5µM for 4h) was included as a positive control. “Light” 
indicates a short exposure and “dark” a longer exposure of the same blot. Ku80 was 
used as a loading control. Note: Chemical library screen was performed by Ioanna 
Papandreou, postdoctoral fellow at Stanford University. 
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specifically blocked or activated ATF4 levels without significantly affecting control CMV-
luc levels were further tested.  Four compounds exhibiting these properties with an IC50 
< 10µM were identified.  Of these, three compounds turned out to be false-positives, as 
they failed to significantly modify ATF4-Luc activity in triplicate experiments (data not 
shown).  One compound, E235, was a potent activator of ATF4 (Fig. 6B).  Since 
pharmacological activators of the UPR (e.g., Bortezomib, thapsigargin, etc.) can have 
potent antiproliferative and antitumor effects, we decided to further investigate the in 
vitro properties of E235 against a variety of normal and transformed cells. 
 
E235 increases ATF4 expression in transformed cells. Since E235 was identified in a 
chemical library screening for modulators of ATF4 expression, we first assessed the 
effect of this drug on ATF4 mRNA expression. E235 caused a dose-dependent increase 
in luciferase activity from a reporter plasmid containing the 5’ UTR of the ATF4 mRNA 
fused to the luciferase gene (Fig. 6A,C). To confirm that this increase in luciferase 
activity corresponded to an increase in ATF4 protein levels, nuclear extracts from 
HT1080, B16F10, and AG1522 cells treated with increasing doses of E235 were 
subjected to immunoblotting. A dose-dependent increase in ATF4 protein levels was 
seen only in the HT1080 and B16F10 cells (Fig. 6D,E). There was no appreciable 
induction of ATF4 protein in the normal diploid AG1522 human fibroblasts in response to 
E235, whereas thapsigargin induced a potent upregulation of ATF4 levels (Fig. 6F), 
suggesting that this effect is restricted to transformed cells. 
 
E235 activates the ISR in transformed cells. Next, we analyzed the effects of E235 on 
the induction of the UPR and the ISR, since ATF4 is a common downstream effector of 
these two pathways. An intermediate dose of 1µM E235 was added to HT1080 cells for 
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various lengths of time. HT1080 cells were also treated with increasing doses of E235 
for 4h. There was a time- and dose-dependent induction of p-eIF2α in response to E235 
(Fig. 7A,B). However, in contrast to thapsigargin, E235 failed to induce any significant 
change in the electrophoretic mobility of PERK. In agreement with the ATF4 results, this 
dose-dependent increase in p-eIF2α was not seen in the AG1522 cells (Fig. 7C). To 
determine if E235-mediated phosphorylation of eIF2α was a consequence of the 
activation of the UPR, the levels of spliced XBP-1 (XBP-1s) mRNA in HT1080 cells 
treated with E235 were evaluated by quantitative PCR. A very modest increase in XBP-
1s was seen at 4h, but this was much less than the levels induced by thapsigargin, 
which suggested that E235 is acting primarily through the ISR (Fig. 7D). To determine if 
the E235-induced phosphorylation of eIF2α was PERK-dependent, immunoblotting for 
total PERK and p-eIF2α in both empty lentiviral vector- and shPERK-transduced HT1080 
cells, as well as in PERK wildtype and knockout transformed MFs, was performed. An 
increase in p-eIF2α was observed with 2h of E235 treatment in both the empty vector 
cells and the shPERK cells, suggesting that activation of the ISR by E235 was PERK-
independent (Fig. 8A). Similar results were obtained in the MFs, although there was a 
small decrease in p-eIF2α at 4h in the PERK null MFs compared to MFs with wildtype 
PERK (Fig. 8B). Additionally, to determine if GCN2 plays a role in E235 induction of 
ATF4, the levels of p-eIF2α were assessed by immunoblotting in GCN2+/+ and GCN2-/- 
MFs and in shNT and shGCN2 HT1080 cells. The levels of p-eIF2α were actually 
increased by E235 in the shGCN2 HT1080 cells, while GCN2 status had no bearing on 
the E235-induced phosphorylation of eIF2α in MFs (Fig. 8C,D). These results indicate 
that E235 is not activating the ISR through GCN2. Moreover, we tested whether the 
activation of the ISR was due to inhibition of the proteasome by treating HT1080 cells 
with various doses of E235 and comparing the levels of ubiquitinated proteins to those in  
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Fig. 7. E235 induces the ISR in transformed cells. A-B) HT1080 cells were treated 
with either 1µM E235 for various times (A) or with increasing doses of E235 for 4h (B) 
and activation of the ISR was examined by blotting whole cell lysates for phosphorylated 
eIF2α (p-eIF2α) and PERK. Lysate from HT1080 cells treated with 0.5µM Tg for 1h was 
used as a positive control. Ku80 was used as a loading control. C) AG1522 cells were 
treated with increases doses of E235 and levels of p-eIF2α were determined by 
immunoblotting. Ku80 was used as a loading control. D) Quantitative PCR was used to 
determine the levels of XBP1-s mRNA in HT1080 cells after various lengths of 1µM 
E235 treatment. Treatment with 0.5µM Tg for 4h was used as a positive control. All  
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(Fig. 7 continued) 
XBP1-s values were normalized to 18s rRNA levels and then to the DMSO-treated 
control (0µM) value. **p<0.01 as compared to control (0µM) by student’s t-test (one 
sample read in triplicate). E) The effect of E235 treatment on proteasome function was 
assessed by immunoblotting for ubiquitin. HT1080 cells were treated with E235 (0, 0.5, 
1, or 10µM) for either 4 or 8 hours, and then whole cell lysates were analyzed for 
ubiquitinated proteins. Treatment with the proteasome inhibitor MG132 (20µM) was used 
as a positive control. 
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Fig. 8. The effect of E235 on PERK and GCN2 activity. A) Activation of the ISR in 
empty vector and shPERK transduced HT1080 cells treated with E235 was examined by 
immunoblotting whole cell lysates for p-eIF2α and PERK. Cells treated for 1h with 0.5µM 
Tg were used as a positive control. B) The experiment in (A) was repeated in PERK +/+ 
and PERK -/- MFs. C) HT1080 shNT and shGCN2 cells were treated with E235 and 
whole cell lysates were immunoblotted for p-eIF2α and GCN2. Glutamine deprivation for 
7h was used as a positive control for GCN2 activation. D) The experiment in (C) was 
repeated using GCN2 +/+ and GCN2 -/- MFs. Ku80 was used as a loading control in all 
panels. 
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cells treated with the known proteasome inhibitor MG132 (Fig. 7E). Minimal 
accumulation of ubiquitinated proteins was seen with even the highest concentration of 
E235, indicating that proteasomal activity was not being inhibited at doses which induce 
ATF4 expression. 
 
E235 inhibits cell proliferation. Previously, it was shown that while induction of ATF4 
is generally cytoprotective, prolonged or excessive activation of the UPR and ISR can be 
cytotoxic (Fels et al, 2008; Zinszner et al, 1998). Thus, several transformed cell lines 
were treated with E235 and then subjected to an MTT viability assay. All four of the 
cancer cell lines tested exhibited a significant decrease in survival when treated with low 
µM concentrations of E235. E235 caused a dose-dependent decrease in cell viability in 
the HT1080 cells (Fig. 9A). Treatment with 1µM E235 decreased cell viability by over 
75% in the B16F10 and 4T1 cells (Fig. 9A). A dose of 10µM E235 essentially blocked 
the growth of all four cell types. Trypan blue exclusion assays performed under similar 
conditions on HT1080 and B16F10 cells confirmed that E235 dose-dependently 
decreases cell viability (data not shown). Notably, doses as low as 0.25µM were 
sufficient to eliminate cell survival in the RPMI-8226 cells (Fig. 9A). In a clonogenic 
survival assay, 24h of 1µM E235 treatment completely prevented the formation of any 
colonies (Fig. 9B). In addition, HT1080 cells demonstrated a time-dependent decrease in 
cell viability, with 24h of E235 treatment reducing viability by more than 50% (Fig. 9C). 
Treatment of RPMI-8226 cells with E235 for just 8h was enough to abolish any cell 
survival (Fig. 9C). A dose dependent reduction in cell proliferation was also seen in the 
normal AG1522 cells, with 1µM E235 causing a 60-70% decrease in viability (Fig. 9D). 
To determine whether the observed decrease in cell viability was due to apoptosis, 
HT1080 and B16F10 cells were treated with E235 for various times and doses and the  
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Fig. 9. E235 decreases cell proliferation. A) Various cell lines were treated with 
increasing doses of E235 and effects on cell proliferation were assessed using an MTT 
assay. E235 treatment was for either 4 days (4T1 and B16F10) or 5 days (HT1080 and  
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(Fig. 9 continued) 
RPMI-8226). The cell lines tested were HT1080, RPMI-8226, B16F10, and 4T1. All E235  
treatment groups were normalized to DMSO-treated (0µM) controls. **p<0.01, 
***p<0.001 as compared to 0µM controls. B) The impact of E235 on the viability of cells 
was examined using a clonogenic assay. B16F10 cells that had been treated at high 
density for 24h with either DMSO or 1µM E235 were replated at low density and allowed 
to form colonies. Representative plates are shown. C) HT1080 or RPMI-8226 cells were 
treated with 1µM E235 for the indicated time periods. At those times, fresh media without 
E235 was added and cells were allowed to proliferate until the untreated cells reached 
confluence (5 days after initial treatment). Cell proliferation/survival was then measured 
with an MTT assay. D) Cell viability was examined in normal human fibroblasts using the 
MTT assay. AG1522 cells were treated with various doses of E235 for 4 days. All E235 
treatment groups were normalized to untreated controls. ***p<0.001 as compared to 
untreated controls. Data (A,C-D) presented as the mean ± SEM (n=6), and all statistics 
were performed using one-way ANOVA with Tukey’s multiple comparison post-test. E-F) 
Expression of the apoptotic markers c-PARP and cleaved caspase3 (c-casp3), after 
varying lengths and doses of E235 treatment, was examined by immunoblotting in both 
HT1080 (E) and B16F10 (F) cells. Treatments with 1µM Tg (4h) or 0.5µM staurosporine 
(Stauro) (3h) were used as positive controls. Ku80 was used as a loading control.  
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cleavage of PARP (c-PARP) and the processing of caspase3 were examined by 
immunoblotting. While there was a modest increase in the 19kDa cleavage product of 
caspase3 in the HT1080 cells with E235, there was no significant accumulation of the 
17kDa subunit, which was observed in the staurosporine-treated HT1080 cells (Fig. 9E). 
In the B16F10 cells treated with E235 for 24h, there was a small increase in caspase3 
cleavage with increasing dose (Fig. 9F). In both cell lines, the levels of cleaved PARP in 
E235-treated samples remained the same as those in untreated controls. Together, 
these results suggest that apoptosis has a minimal contribution to the decrease in cell 
viability and proliferation induced by E235. 
 
ATF4 dependence of E235-induced effects. Because we have shown that treatment 
with E235 increases ATF4 expression, we sought to determine if cell viability during 
E235 treatment was dependent on ATF4 expression. An MTT assay was performed on 
E235-treated HT1080 cells stably transfected with either non-targeting shRNA (shNT) or 
shRNA directed at ATF4 (shATF4) (Fig. 10A). We observed a substantial decrease in 
cell viability in shATF4 cells compared to shNT cells at E235 doses of 0.5 and 1µM (Fig. 
10B). In agreement with these results, a significant decrease in shATF4 cell viability 
compared to shNT cells was seen with low doses of E235 treatment in a clonogenic 
survival assay (Fig. 10C). However, 10µM doses of E235 eliminated cell survival in both 
shNT and shATF4 cells. Altogether, these results indicate that the induction of ATF4 
confers cytoprotection to cells treated with low µM doses of E235.  
 
E235 is a potent inducer of cellular senescence. While assaying the antiproliferative 
effects of E235 on transformed cells, we observed that cells treated for at least 48h with 
lower doses of E235 (0.25-1µM) increased in size and displayed characteristics  
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Fig. 10. Ablation of ATF4 enhances E235-induced decrease in cell viability. A) 
Western of nuclear lysates from HT1080 shNT and shATF4 cells treated with DMSO or 
Tg (4h) showing the efficiency of ATF4 knockdown. Ku80 was used as a loading control. 
B) The importance of ATF4 for the E235-induced reduction in cell viability was assessed 
with an MTT assay using HT1080 shNT or shATF4 cells. Cells were treated with various 
doses of E235 for 5 days. All E235 treatment groups were normalized to DMSO-treated 
(0µM) controls. **p<0.01 or ***p<0.001 as compared to 0µM controls using one-way 
ANOVA with Tukey’s multiple comparison post-test. C) The influence of ATF4 
expression on the viability of cells treated with E235 was also analyzed with a 
clonogenic assay. Surviving fraction of each cell type is plotted vs. the log of the E235 
concentration. Each data point is n=3. ***p=0.0003 for shNT vs. shATF4 at 1µM E235 by 
student’s t-test.  
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consistent with a senescent phenotype (Fig. 11A). A small augmentation of cell size was 
also seen in normal mouse (ALF) and human (AG1522) cells, but it was not as extensive 
as that observed in the transformed cells (Fig. 11A). We therefore assayed for SA-β-gal 
activity, a commonly used senescence marker. Both HT1080 and B16F10 cells exhibited 
a dramatic increase in perinuclear SA-β-gal staining after 48h of treatment with lower 
doses of E235, with almost all of the cells treated with 1µM E235 being positive for β-gal 
expression (Fig. 11B). Interestingly, the morphological changes were not dependent on 
either ATF4 or PERK expression, as HT1080 cells with either shPERK or shATF4 still 
adopted the senescence-like morphology upon E235 treatment (Fig. 12A,B). In addition, 
these E235-induced morphological changes appeared to be irreversible, as cells 
retained their senescence-like appearance even 10 days after removal of the drug (data 
not shown). To determine the kinetics of the morphological changes, HT1080 and 
B16F10 cells were imaged via live microscopy (data not included). We observed that the 
increase in cell size with 1µM E235 commenced approximately 24h post-treatment. We 
also noted a substantial reduction in cell proliferation in the E235-treated cells, which 
was consistent with the results from the MTT assays and supported our hypothesis that 
E235 was causing cells to undergo senescence. 
 
To further examine the possibility that E235 induced senescence, levels of the cyclin-
dependent kinase inhibitors (CDKI) p16, p21, and p27 with and without E235 treatment 
were assessed at various time points. Increased expression of these CDKIs has been 
correlated to the induction of cellular senescence (Ewald et al, 2010). Both HT1080 and 
B16F10 cells displayed elevated levels of p21 with 1µM E235 at 8 and 16h (Fig. 13A,B). 
In addition, a dose-dependent increase in p21 protein expression was seen with 24h of 
E235 treatment in the HT1080 cells (Fig. 13A). However, there was no appreciable  
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Fig. 11. E235 induces a senescence-like phenotype at low doses. A) Phase 
microscopy images of B16F10, mouse ALF, and AG1522 cells after 3, 5, and 2 days, 
respectively, of DMSO or E235 treatment. Original objective magnification was 10x. B) 
Bright field microscopy images of B16F10 (top) and HT1080 (bottom) cells stained for 
SA-β-gal activity after 3 days of treatment with E235 or DMSO. Original magnification 
was 10x. 
A
B
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Fig. 12. Senescence induced by E235 is PERK- and ATF4-independent. A) Phase 
microscopy images of empty vector and shPERK transduced HT1080 cells after 2d of 
treatment with DMSO or E235. B) Phase microscopy images of HT1080 shNT and 
shATF4 cells after treatment with DMSO or E235 for 4d. Original objective magnification 
was 10x (A-B). 
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Fig. 13. E235 upregulates p21 expression. A-B) HT1080 (A) and B16F10 (B) cells 
were treated for various lengths and doses of E235, and expression of the senescence 
regulators p21 and p27 were analyzed by immunoblotting. Ku80 expression was used as 
a loading control. C) Expression of the senescence marker p16 was examined in 
HT1080 cells treated with DMSO or 1µM E235 for 24 and 48h. Ku80 was used as a 
loading control. 
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difference in p27 levels in either cell type at any time point or any dose of E235 (Fig. 
13A,B). We also did not observe any changes in p16 expression at either 24 or 48h after 
E235 treatment in the HT1080 cells (Fig. 13C). 
 
E235-induced senescence is not dependent on p21 or p53. Since E235 was shown 
to induce p21 protein expression, we wanted to investigate the role of p21 in E235-
induced cellular senescence. B16F10 cells were transfected with a plasmid expressing 
shRNA directed at p21 (shP21) or with an empty vector plasmid (pLKO), and near 
complete knockdown of p21 was confirmed by Western blotting (Fig. 14A). These cells 
were then stained for SA-β-gal activity after 48h of treatment with low doses of E235. 
Unexpectedly, shP21 cells were still able to assume senescence-like morphology and to 
exhibit staining for SA-β-gal activity (Fig. 14B). However, the p21 knockdown cells still 
showed a small induction of p21 protein expression after E235 treatment, which could 
have been sufficient for senescence to occur (Fig. 14A). To further test the role of p21, 
we treated p21+/+ and p21-/- immortalized MFs with E235. We observed no difference 
in the ability of p21-/- vs. p21+/+ MFs to undergo senescence (Fig. 14C). Nevertheless, 
there was a significant reduction in cell viability in two separate clones of shP21 cells 
treated with E235 (0.5 or 1µM) compared to pLKO-transfected controls (Fig. 14D). 
These results indicate that p21 plays a role in cellular survival but not senescence in 
E235-treated cells. 
 
Because p53 is frequently involved in, although not absolutely required for, induction of 
cellular senescence (Ben-Porath & Weinberg, 2005; Chang et al, 1999), we tested the 
effects of E235 on p53 wild-type and knockout Ras- and myc-transformed MFs.  
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Fig. 14. E235-mediated senescence is p21- and p53-independent. A) Levels of p21 
in B16F10 cells stably transfected with either pLKO or shP21 were treated with 0, 1 or 
5µM E235 and analyzed by immunoblotting. β-actin was used as a loading control. B) 
B16F10 pLKO or shP21 cells (two different clones) were treated with E235 for 48h and 
then stained for SA-β-gal activity. Original objective magnification was 10x. C) Phase  
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(Fig. 14 continued) 
microscopy images of p21 +/+ and -/- MFs treated with DMSO or 1µM E235 for 3d.  
Original magnification was 10x.  D) The effect of knocking down p21 expression on cell 
viability was examined using an MTT assay. B16F10 pLKO or shP21 cells were treated 
with various doses of E235 for 4 days. All treatment groups were normalized to their 
respective DMSO-treated (0µM) controls. ****p<0.0001 for each shP21 clone as 
compared to pLKO cells treated with the same dose. Representative data from one of 
two separate experiments is shown and is presented as the mean ± SEM (n=6). 
Statistics were performed using one-way ANOVA with Tukey’s multiple comparison post-
test. E) Phase microscopy images of p53 +/+ and -/- MFs (Ras- and myc-transformed) 
treated with DMSO or 1µM E235 for 2d. Original magnification was 20x. 
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Interestingly, p53 was also found to be dispensable for E235-induced senescence, as 
p53 knockout cells retained their ability to senesce under low doses of E235 (Fig. 14E). 
 
E235 induces a G2/M arrest. Consistent with the induction of senescence, we also 
observed that low doses of E235 caused cells to undergo G2/M arrest. The percentage 
of HT1080 cells in the G2/M phase of the cell cycle was significantly increased by E235 
treatment, starting as early as 8h and becoming more evident at 16 and 24h (Fig. 15A). 
This E235-induced increase of cells in G2/M was accompanied by a concomitant 
reduction of cells in S phase, with only 14.5% of E235-treated cells in S phase at 24h 
compared to 38.8% of DMSO-treated cells (Fig. 15A). A small rise in the amount of cells 
in G1 was also observed. In addition, a substantial increase of cells in G2/M and 
concurrent decrease in S phase cells was seen even at 8h when B16F10 cells were 
treated with E235 (Fig. 15B). 
 
Effects of E235 on DNA damage signaling pathways and DNA integrity. Since the 
majority of chemotherapeutic agents that cause cellular senescence have been shown 
to induce DNA damage, we next examined the effects of E235 on stabilization and 
phosphorylation of p53, a key regulator of the DNA damage response (Levine, 1997). 
Increasing doses of E235 corresponded to an increase in p53 protein levels in both 
normal (AG1522) and transformed (HT1080) cells (Fig. 16A). We also analyzed the 
phosphorylation of p53 at Ser15, which is associated with activation of the DNA damage 
response (Chao et al, 2000). In AG1522 cells, 1µM E235 induced a small amount of 
Ser15 phosphorylation, while 5 and 10µM doses produced p-Ser15 levels comparable to 
those seen in cells treated with 4Gy (Fig. 16B). We also observed a dose-dependent 
increase in p-Ser15 levels in E235-treated HT1080 and in B16F10 cells (Fig. 16B,C).  
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Fig. 15. E235 causes cell cycle arrest at G2/M. A-B) HT1080 (A) and B16F10 (B) cells 
were treated with 1µM E235 for various lengths of time and then stained with PI. PI-
stained cells were analyzed for cell cycle distribution using flow cytometry. Each graph 
depicts fluorescent intensity vs. cell count of about 20,000 total events. The percentages 
of cells in G1, S, and G2 phases are listed within each graph.  
  
A B
43 
 
 
Fig. 16. E235 promotes DNA damage signaling. A-B) AG1522 and HT1080 cells were 
treated with increasing doses of E235 (for 4h), and the stabilization of p53 was 
determined by immunoblotting whole cell lysates for total p53 (A). In addition, the 
induction of p53 phosphorylation was assessed by blotting with an antibody specific for 
phosphorylation of p53 on Ser15 (B). As a positive control, AG1522 cells were irradiated 
with 4Gy and harvested 2h later. C) B16F10 cells were dosed with increasing amounts 
of E235 for 4h and then levels of p-p53 (Ser15) were analyzed by immunoblotting. D) 
Unsynchronized and synchronized (with 400ng/ml of nocodazole (Noc) for 16h) HT1080 
cells were analyzed for p-Chk2 (Thr68) levels after 2h of treatment with either DMSO or 
1µM E235. E) Both AG1522 and HT1080 cells were treated with various doses of E235 
and γ-H2AX levels were determined by immunoblotting. Cells treated with 4Gy of 
radiation and harvested 30 min later were used as a positive control. Ku80 expression 
was used as a loading control in A-E.  
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Levels of p-Chk2 and γ-H2AX were then examined to see if treatment with E235 also led 
to activation of the DNA damage response. E235 treatment caused an increase in the 
levels of phosphorylated Chk2 in both synchronized (with nocodazole) and 
unsynchronized HT1080 cells (Fig. 16D). In HT1080 cells, there was a significant 
induction in phosphorylation of H2AX with increasing doses of E235 (Fig.16E). This 
effect was significantly attenuated in AG1522 cells, where a concentration of at least 
5µM E235 was required to see any γ-H2AX (Fig. 16E). The induction of the DNA 
damage response was not due to the generation of reactive oxygen species (ROS), 
however, even in cells treated with doses of up to 10µM E235 (Fig. 17A). To determine 
whether the activation of DNA damage response signaling was due to physical DNA 
damage, a comet assay was performed on AG1522 and HT1080 cells. E235 did not lead 
to DNA strand breaks in the AG1522 cells, as evidenced by the similar tail moments 
between the DMSO-treated and E235-treated cells (Fig. 17C). Even more surprising was 
the finding that E235 did not cause an increase in tail moment in the HT1080 cells, 
despite the high levels of p53, Chk2 and H2AX phosphorylation (Fig. 17B,C). Therefore, 
E235 appears to elicit a DNA damage response without inducing physical DNA damage. 
 
E235 is not an Aurora kinase or topoisomerase inhibitor. To further explore the 
possible mechanism of action of E235, we tested to see if this drug could be a 
topoisomerase inhibitor, since these induce DNA damage signaling and can cause 
senescence (Ewald et al, 2010). B16F10 cells were treated with two concentrations of 
either a topoisomerase I inhibitor (camptothecin) or a topoisomerase II inhibitor 
(etoposide), and nuclear extracts were immunoblotted for ATF4. Neither drug elicited 
any induction of ATF4 at the examined concentrations – concentrations which were high 
enough to cause phosphorylation of p53 on Ser15 (Fig. 18A). Although this was not a  
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Fig. 17. E235 does not induce DNA double strand breaks. A) ROS levels in cells 
treated with E235 were determined using DCF-DA. Fluorescent intensity vs. cell count is 
depicted for each treatment. Each line represents about 20,000 cells. H2O2 was used as 
a positive control. B-C) A comet assay was performed on E235-treated AG1522 and 
HT1080 cells to assess DNA double strand breaks. Cells were treated with E235 for 
24h. Tail moments of individual cells were quantified and the median tail moment is 
presented in the graph (C). Cells irradiated with 4Gy (assayed immediately) were used 
as a positive control. Representative images of the treatment groups in HT1080 cells are 
shown (B). Note: Experiment in (B) and (C) was performed by David Guttmann. 
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Fig. 18. E235 is not a topoisomerase or an Aurora kinase inhibitor. A) B16F10 cells 
were treated with two doses of either etoposide (Etopo) or camptothecin (Campto) for 
4h, and then nuclear extracts were blotted for ATF4 and p-p53 (Ser15). Thapsigargin 
(0.5µM for 4h) was used as a positive control for ATF4 induction. B) B16F10 cells were 
treated with increasing concentrations of Aurora A (Aur A) Inhibitor for 4h and nuclear 
extracts were blotted for ATF4 expression. Thapsigargin (0.5µM for 4h) was used as a 
positive control. C) The levels of p-Aurora A (p-Aur A; Thr288) and p-PLK1 (Thr210) 
were analyzed by immunoblotting whole cell lysates from unsynchronized or 
synchronized (with 400ng/ml of nocodazole for 16h) HT1080 cells treated for 4h with 
either DMSO, 1µM E235, or 0.4µM Aurora A inhibitor (Aur AI). D) Lysates from (C) were 
subjected to immunoblotting for p-histone H3 (p-His H3; Ser10). Aur AI was used here 
as a negative control. Ku80 was used as a loading control in A-D. 
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direct assay for inhibition of topoisomerase by E235, we concluded that E235 was not 
affecting topoisomerase activity because E235 induces ATF4 and topoisomerase 
inhibitors do not. 
  
Aurora kinases are essential for proper centrosome maturation and separation and for 
activation of the spindle assembly checkpoint during mitosis (Lens et al, 2010). Since it 
has been reported that inhibition of Aurora kinases A and B can cause cellular 
senescence, we examined the effect of E235 on these kinases (Huck et al, 2010; Kim et 
al, 2011). First, it was confirmed that a specific Aurora kinase A inhibitor does indeed 
cause a dose-dependent increase in ATF4 expression in B16F10 cells, with 4µM of 
Aurora A inhibitor inducing as much ATF4 protein as thapsigargin (Fig. 18B). We further 
investigated the possibility that E235 was inhibiting Aurora kinase A by probing the 
activation of Aurora A and its downstream target polo-like kinase 1 (PLK1) in 
unsynchronized and synchronized (with nocodazole) HT1080 cells. As expected, since 
nocodazole induces activation of the spindle assembly checkpoint, levels of p-Aurora A 
and p-PLK1 were potently elevated with nocodazole treatment (Fig. 18C). The Aurora A 
inhibitor almost eliminated the phosphorylation of these two proteins; however, treatment 
with E235 had no effect on their activation, establishing that E235 is not an Aurora A 
inhibitor (Fig. 18C). To assess whether E235 was inhibiting Aurora B, phosphorylation of 
histone H3 at Ser10, which is executed by activated Aurora B, was examined by 
immunoblotting lysates of HT1080 cells with or without nocodazole treatment. Again, 
nocodazole potently induced the phosphorylation of histone H3. E235, however, did not 
change the level of p-histone H3, indicating that E235 is not an Aurora B inhibitor either 
(Fig. 18D).  
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Knockdown of ATF4 decreases γ-H2AX levels. In order to elucidate how the 
expression levels of ATF4 altered clonogenic survival of E235-treated cells, several 
assays were performed using the HT1080 shNT and shATF4 cells. No difference in cell 
cycle distribution between shNT and shATF4 HT1080 cells was seen at 8h, 16h, or 24h 
after treatment with 1µM E235 (data not shown). There was also no defect in the ability 
of the ATF4 knockdown cells to senesce when treated with E235 (Fig. 12B). 
Interestingly, the induction of γ-H2AX by E235, as measured by immunoblotting, was 
attenuated in HT1080 cells expressing shATF4 (Fig. 19A). Corroborating this finding 
were immunofluorescent data that showed shATF4 cells treated with E235 had reduced 
γ-H2AX signal compared to the shNT cells (Fig. 19B,C). Together, these results suggest 
that the DNA damage signaling could be partially dependent on ATF4 expression.  
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Fig. 19. Knockdown of ATF4 reduces γ-H2AX levels in E235-treated cells. A) 
HT1080 shNT and shATF4 cells were treated with increasing doses of E235, and the 
levels of γ-H2AX were analyzed by immunoblotting. Values below the blots represent 
fold change in γ-H2AX pixel intensity over DMSO-treated shNT cells after normalization 
to Ku80 levels. Cells irradiated with 4Gy (harvested after 15min) were used as a positive 
control. The immunoblots shown are representative of 3 independent experiments. B) 
HT1080 shNT and shATF4 cells were treated with two different doses of E235 for 4h, 
fixed and immunofluorescently stained for γ-H2AX foci. The average nuclear γ-H2AX 
fluorescent signal of at least 100 cells per treatment is shown. *** p<0.001 and **** 
p<0.0001 by student’s t-test. C) Representative images of γ-H2AX fluorescence from 
each of the treatment groups in (B). 
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B. Materials and Methods 
Chemicals 
E235 (E235-1756) was obtained from ChemDiv (San Diego, CA), the company that 
provided the chemical library for the original screen. The E235 chemical structure was 
drawn using KnowItAll® Informatics System from Bio-Rad (Hercules, CA).  All cell 
culture reagents were from Gibco, except MEM (minimum essential medium), which was 
from Mediatech (Manassas, VA). Thapsigargin (Tg), puromycin, MG132, etoposide, 
camptothecin, nocodazole, bovine serum albumin, Triton X-100 and poly-L-lysine, were 
purchased from Sigma-Aldrich (St. Louis, MO). Staurosporine was from MP Biomedicals 
(Solon, OH). Aurora A inhibitor was gifted by Dr. Eric Brown’s lab (University of 
Pennsylvania, Philadelphia, PA) and was originally purchased from Selleck Chemicals 
(Houston, TX).  
 
Cell culture and generation of stable cell lines 
HT1080 human fibrosarcoma cells were obtained from ATCC (Manassas, VA), B16F10 
mouse melanoma cells were a gift from Dr. Sandra Ryeom (University of Pennsylvania, 
Philadelphia, PA), p21+/+ and p21-/- MFs were a gift from Dr. Charles Scherr (St. Jude’s 
Children’s Hospital, Memphis, TN), p53+/+ and p53-/- MFs were a kind gift from the lab 
of Dr. Scott Lowe (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), PERK+/+, 
PERK-/-, GCN2+/+ and GCN2-/- MFs were gifted by Dr. David Ron (University of 
Cambridge, Cambridge, UK) and 4T1 mouse mammary carcinoma cells were a gift from 
Steve Albelda (University of Pennsylvania, Philadelphia, PA). These cells were cultured 
in Dulbecco's modified Eagle medium (DMEM). RPMI-8226 human multiple myeloma 
cells (ATCC) were grown in RPMI.  Mouse adult lung fibroblasts (ALFs) were isolated in 
our lab from adult female mice (C57BL/6J, Jackson Laboratory, Bar Harbor, ME) and 
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cultured in DMEM/F12. In all cases, the media was supplemented with penicillin, 
streptomycin, and 10% fetal bovine serum (FBS). AG1522 cells (Coriell Cell Repository, 
Camden, NJ) were grown in MEM supplemented with penicillin, streptomycin, 15% FBS, 
and non-essential amino acids (NEAA). HT1080 shATF4, shGCN2 and GCN2-/- MF 
cells were also supplemented with NEAA, as well as 55µM β-mercaptoethanol. To 
establish cells with stable knockdown of p21, B16F10 cells were transfected with pLKO 
or pLKO-shP21 plasmids (Sigma-Aldrich) using Lipofectamine2000 (Invitrogen, Grand 
Island, NY) and selected with puromycin (2µg/ml and reduced to 0.5 µg/ml for 
maintenance). HT1080 empty lentiviral vector and shPERK cells were grown with 
0.5µg/ml puromycin to maintain plasmid expression.  
 
Chemical library screen 
The ATF4-Luc fusion gene construct was used in the screen (see results section). 4000 
cells/well were plated for 24 hrs in 384 well microplate format prior to induction of ER 
stress with thapsigargin (250nM) for 16h and exposure to one compound per well (10-
20µM).   
 
Luciferase reporter assay 
HT1080 cells expressing either a constitutively active CMV-driven luciferase plasmid 
(CMV-Luc) or a plasmid where the expression of the luciferase gene was driven by the 
5’-UTR of the ATF4 mRNA (ATF4-Luc) were seeded in a 24-well plate, and then treated 
in duplicate the following day. After 4 or 8 hours of treatment, luciferase activity was 
quantified using the Luciferase Assay System from Promega (Madison, WI). Each well 
was read in triplicate in a white 96-plate. Luciferase activity in the ATF4-Luc cells was 
normalized to the activity in the corresponding CMV-Luc cells. 
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Immunoblot analysis 
Whole cell extracts were obtained by lysing cells with a solution of PBS, NP-40 (1%) 
(Roche Applied Science, Indianapolis, IN), cOmplete mini protease inhibitor tablets 
(Roche Applied Science), and phosphatase inhibitor cocktail (Sigma). Nuclear proteins 
were extracted by first lysing the outer membranes of cells with a buffer solution 
containing Triton X-100 (0.5%), cOmplete mini protease inhibitor tablets, and 
phosphatase inhibitor cocktail. The nuclei were then lysed with NP-40 (0.1%) in the 
presence of the protease and phosphatase inhibitors. Cells were harvested for γ-H2AX 
analysis by direct lysis in SDS (1.5%) sample buffer. Immunoblotting was performed as 
previously described (Koumenis et al, 2002), with the exception that proteins were 
transferred to polyvinylidene fluoride membranes. Protein concentration was determined 
using Pierce® 660 nm Protein Assay Reagent (Thermo Scientific, Waltham, MA), in 
accordance to the manufacturer’s instructions. Primary antibodies against the following 
proteins were used: ATF4, p53, p21 (Santa Cruz Biotechnology, Santa Cruz, CA), Ku80, 
eIF2α, p-eIF2α, PERK, p-p53 (Ser15), cleaved caspase-3, p27, ubiquitin, p-Chk2 
(Thr68), cleaved PARP, p-Aurora A (Thr288), p-histone H3 (Ser10) (Cell Signaling 
Technology, Danvers, MA), β-actin (Sigma-Aldrich), γ-H2AX (Upstate Biotechnology, 
Inc., Lake Placid, NY) and p21 (BD Pharmingen, San Diego, CA). The p-PLK1 (Thr210) 
antibody was provided to us by Dr. Eric Brown’s lab. Horseradish peroxidase-conjugated 
anti-mouse or anti-rabbit secondary antibodies (Thermo Scientific) were used to detect 
the primary antibodies, and then the immunoreactive bands were visualized on x-ray film 
(Thermo Scientific) using AmershamTMECLTM or ECL Plus Western Blotting Detection 
Systems (GE Healthcare, Fairfield, CT). Pixel intensity of individual bands was quantified 
using ImageJ software (National Institutes of Health, Bethesda, MD). 
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Real-time quantitative PCR 
RNA was isolated by using TRIzol® Reagent (ambion, Carlsbad, CA) and following the 
protocol provided with it. Reverse transcription was performed using AMV Reverse 
Transcriptase (Promega). Real-time quantitative PCR was done using Power SYBR® 
Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and was analyzed with the 
Applied Biosystems 7300 Real-Time PCR System. The relative mRNA levels were 
quantified using the standard curve method. PCR primers were purchased from 
Invitrogen. The following primers were used: human XBP1s-F: 5’-
CCGCAGCAGGTGCAGG, and XBP1s-R: 5’-GAGTCAATACCGCCAGAATCCA; human 
18s rRNA-F: 5’-CAATTACAGGGCCTCGAAAG, and 18s rRNA-R: 5’-
AAACGGCTACCACATCCAAG. 
 
Cell viability assay 
Cell viability was analyzed using the Cell Proliferation Kit I (MTT assay) (Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s protocol. Briefly, cells 
were seeded at low density in 24-well plates, and then treated in duplicate the following 
day. Once the DMSO-treated cells reached confluence, the MTT assay was started. To 
assess the effect of treatment length on cell viability, cells were plated at low density and 
treated for various lengths of time. The media with E235 was then removed and 
replaced with normal media and cells were allowed to proliferate until the untreated cells 
reached confluence (5 days after initial treatment).  Each well was read in triplicate in a 
96-well plate at absorbances of 550 and 690nm. 
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Clonogenic survival assay 
Cells were plated at high density and allowed to attach overnight. They were then 
treated with E235 for 24 hours, at which time the cells were trypsinized and reseeded at 
low density in media without E235. The cells were incubated at 37°C for several days 
until colonies were of sufficient size to count. The colonies were fixed with 10% 
methanol/10% acetic acid and then stained with 0.4% crystal violet. Colonies were 
scanned and counted with an Oxford OptronixGelCount™ and its accompanying 
software (Oxford, UK).  
 
Live cell imaging 
Cells were seeded at low density on 8-well chambered cover glass slides. Cells were 
viewed with a Leica AF6000 microscope (Wetzlar, Germany) at 37°C with 5% CO 2, and 
still images were captured every 20 minutes for 50 hours. Images were viewed and 
analyzed with Leica Application Suite AF.  
 
SA-β-galactosidase staining 
Staining for senescence-associated β-galactosidase (SA-β-gal) activity was performed 
using the Senescence β-Galactosidase Staining kit (Cell Signaling Technology) 
according to the instructions provided by the manufacturer. Brightfield images were 
captured on a Nikon Eclipse TE2000-U (Tokyo, Japan) using Image-Pro Plus 6.0 
software (MediaCybernetics, Rockville, MD).  
 
Cell cycle analysis 
Cells were treated with DMSO or E235 for 8h, 16h, or 24h and then harvested with 
trypsin. Harvested cells were washed, resuspended in PBS with 1%FBS, and fixed with 
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cold ethanol. Fixed cells were washed, incubated in phosphate-citric acid buffer for 5 
minutes and then resuspended in PI/RNase solution (PBS, RNase, and 50µg/ml 
propidium iodide) for staining. The cells were incubated in this solution for 15 minutes at 
37°C in the dark and then analyzed by flow cytometr y with a BD FACSCalibur (BD 
Biosciences, San Jose, CA) and with FlowJo software (Tree Star, Inc., Ashland, OR). 
 
ROS assay 
B16F10 cells were treated with DMSO or various doses of E235 for 4h or with 50µM 
H2O2 for 2h. Cells were trypsinized, resuspended in PBS containing 10µM 2′,7′-
dichlorofluorescin diacetate (DCF-DA) (Sigma-Aldrich), and incubated at 37°C for 30min. 
The cells were then spun down, resuspended in PBS, and analyzed by flow cytometry 
with a BD FACSCalibur (BD Biosciences) and with FlowJo software (Tree Star, Inc.). 
 
Comet assay  
DNA damage was investigated by the alkaline comet assay using the Trevigen Comet 
Assay™ kit (Trevigen Inc., Gaithersburg, MD).  Briefly, cells were trypsinized and 
resuspended in cold PBS at 1 × 105 cells/ml.  An aliquot of this single cell suspension 
was diluted 1:10 in LM Agarose. 50 µl of this suspension was added immediately to a 
CometSlide™ which was incubated at 4°C in the dark for 15 minutes and then immersed 
in pre-chilled lysis solution at 4°C for 30 min.  T he DNA was denatured in an alkaline 
solution (300 mM NaOH, 1 mM EDTA, pH>13) for 60 min at room temperature. Slides 
were subjected to electrophoresis under alkaline conditions (30 mM NaOH, 2 mM 
EDTA), at 4°C in the dark at 0.6 V/cm with a curren t of 35-40 mA for 25 minutes, rinsed 
twice in H2O, and once in 70% EtOH, for five minutes each at room temperature.  Slides 
were dried at 42°C and stained with SYBR green for 5 minutes at 4°C in the dark.  DNA 
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comets were visualized on an Olympus IX51 fluorescence microscope.  Median tail 
moment was recorded from 100 comets per sample and quantified using Comet Assay 
IV software (Perceptive Instruments, UK). 
 
γ-H2AX immunofluorescence 
Cover slips were placed in 6-well plates, coated with a poly-L-lysine solution for 5min, 
dried for 2h, and then sterilized for 15min with UV light. Cells were seeded directly onto 
coverslips and incubated overnight. E235 was added to the cells for 4h. The cells were 
then fixed with neutral buffered formalin solution and incubated with the γ-H2AX primary 
antibody (Millipore) in permeabilization buffer (1% bovine serum albumin and 0.5% 
Triton X-100 in PBS) for 1h at room temperature. Alexa Fluor 488 secondary antibody 
(Molecular Probes, Grand Island, NY) in permeabilization buffer was then added to the 
cells for 1h at room temperature. The cover slips were mounted to slides using 
VECTASHIELD with DAPI (Vector Laboratories, Burlingame, CA) and sealed with clear 
nail polish. Nuclei and γ-H2AX foci were visualized using a Zeiss Observer.Z1 Live Cell 
microscope and ZEN Blue software (Carl Zeiss Microscopy GmbH, Jena, Germany). 
Quantification of the γ-H2AX signal per cell was performed using the ZEN Blue software 
to determine the intensity mean value of signal in the nucleus. At least 100 cells were 
counted for each treatment group.  
 
Graphing and statistics 
All graphs were generated and all statistics (student’s t-test and one-way ANOVA with 
Tukey’s multiple comparison post-test) were performed with GraphPad Prism software 
(GraphPad Software, Inc., La Jolla, CA).  
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Chapter III: Elucidation of the role of ATF4 in tumor cell 
metastasis 
 
This chapter illustrates our investigation of the influence of ATF4 expression on tumor 
cell migration, lung colonization, and metastasis. The generation of a stable, 
doxycycline-inducible ATF4 knockdown HT1080 cell line is also described. 
 
A. Results 
Influence of ATF4 expression on cell migration and invasion. Because a recent 
study reported that depleting ATF4 decreases the in vitro migration of breast cancer 
cells during hypoxia (Nagelkerke et al, 2013), we examined the effect of ATF4 
expression on the migration of HT1080 human fibrosarcoma cells. To do this, we utilized 
scratch assays and transwell migration assays. When HT1080 cells expressing either a 
non-targeting shRNA (shNT) or shRNA against ATF4 (shATF4) were tested with the 
scratch assay under normoxia, no difference was seen in the rate of scratch closure 
between the two cell lines (Fig. 20A). Next, we assessed the migratory ability of HT1080 
shNT and shATF4 cells under two different conditions using the transwell system. In one 
experiment, the assay was done under hypoxia (0.5%) for 10h and then switched to 
normoxia for 10h before fixing and counting the cells (Fig. 20B). In the second, HT1080 
shNT and two different clones of shATF4 cells were cultured in the transwell system for 
5h during hypoxic conditions (0.5%) before being fixed and counted (Fig. 20C). Both 
experiments gave results that were consistent with the scratch assay, showing no 
difference in migration between the shNT and the shATF4 cells (Fig. 20B,C).  
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Fig. 20. ATF4 expression affects invasion, but not migration, of HT1080 cells. A) 
The migratory ability of HT1080 shNT and shATF4 cells was analyzed with a scratch 
assay under normoxic conditions. The area of the original scratch covered by the 
migrated cells is plotted vs. time. Each point represents the average of three replicates. 
B) HT1080 shNT and shATF4 cells were cultured in transwell migration wells for 10h 
under hypoxia (0.5% O2) followed by 10h under normoxia and migrated cells were 
stained with DAPI and counted. The average of the total number of migrated cells 
counted from each of 3 wells is shown. C) HT1080 shNT and shATF4 (cl.3 and cl.4) 
cells were subjected to a transwell migration assay for 5h under hypoxic (0.5% O2) 
conditions. Each bar represents the mean of the total migrated cells counted from each 
of 3 wells. ns= not significant by student’s t-test.  
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Knockdown of ATF4 prevents lung colonization by human fibrosarcoma cells. To 
determine if ATF4 expression has any effect on the later steps of metastasis, we 
employed a lung colonization assay. HT1080 shNT or two shATF4 clones that were also 
transfected with a constitutively-expressed luciferase plasmid (CMV-Luc) were injected 
into the tail veins of athymic nude mice and bioluminescent imaging was used to monitor 
the formation of lung colonies (Fig. 21A). Since these cells were generated by 
transfecting the CMV-Luc plasmid into cells already expressing each shRNA, the 
luciferase activity of each cell line was analyzed using an in vitro assay. While all cells 
exhibited high luminescence, the activity of the shATF4 cl.3 cells was almost six-fold 
higher than that of the shNT or shATF4 cl.4 cells (Fig. 21B). However, this was 
considered acceptable since this would mean that, hypothetically, smaller colonies could 
be detected in mice injected with the shATF4 cl.3 cells. We then established that the 
cells were viable at the time of injection by imaging the mice 4h after inoculation. Both 
shNT and shATF4 mice showed robust luciferase activity in the chest, due to the arrest 
of the cells in the capillaries of the lungs (Fig. 21C). All mice were imaged weekly to 
monitor the formation of colonies. At one week post-injection, a small amount of signal 
could be detected in the chest area of only the mice injected with HT1080 shNT cells 
(data not shown). The bioluminescent signal continued to increase in the mice with shNT 
cells with each week, while no signal was detected in the mice injected with either 
shATF4 clone (Fig. 21D, 22A). In fact, almost all of the mice inoculated with shNT cells 
developed lung colonies, while none of the mice injected with the shATF4 clones did 
(Fig. 22A,C). The overall survival curves reflected this dramatic difference in lung 
colonization, as all of the mice with HT1080 shNT lung colonies had to be euthanized 
due to tumor-related weight loss (Fig. 22B). In contrast, all of the shATF4-injected mice 
were healthy, some more than 100 days after the intravenous injection (Fig. 22B). 
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Fig. 21. Knockdown of ATF4 prevents fibrosarcoma lung colonization. A) ATF4 
expression in untreated or thapsigargin treated (0.5µM for 4h) HT1080 shNT and 
shATF4 (cl.3 and cl.4) cells was assessed by immunoblotting. Ku80 was used as a 
loading control. B) HT1080 shNT, shATF4 cl.3, and shATF4 cl.4 cells transfected with 
CMV-Luc were assayed for luciferase activity. Columns represent the average of three 
readings of each of two biological replicates. C) Bioluminescent images at 4h post-
injection of mice injected intravenously with HT1080 shNT or shATF4 cl.4 cells. A 
representative mouse from each group is shown. D) Images of bioluminescent signal at 
4 wks after injection of HT1080 shNT, shATF4 cl.3, or shATF4 cl.4 cells via the tail vein. 
All mice from a single experiment are shown. Signal intensity scale applies to all mice.  
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Fig. 22. Ablation of ATF4 abolishes fibrosarcoma lung colonization. A) The average 
bioluminescent signal of the chest/lung area of mice injected intravenously with HT1080 
shNT or shATF4 (clones 3 and 4 combined) is plotted against time. Lines represent the 
average signal from mice injected with shNT (n=6) or shATF4 (n=9) cells. B) Kaplan-
Meier survival curve for mice injected with HT1080 shNT (n=4) or either of the shATF4 
clones (n=8). Note that some of the mice are excluded from these curves because they 
were not kept for long-term survival experiments. *** p=0.0002 by the log-rank test. C) 
Table summarizing the results from all tail vein injection experiments with the HT1080 
shNT and shATF4 (cl.3 and 4 combined) cells. The fractions represent the number of 
mice with bioluminescent signal in the chest over the total number of mice injected with 
that cell type. 
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ATF4 expression has a minimal effect on colonization by murine mammary 
carcinoma cells. We tried to replicate the results seen with the HT1080 cells by using a 
different system, namely 4T1 cells, a highly metastatic mouse mammary carcinoma cell 
line (Aslakson & Miller, 1992). After confirming the knockdown of ATF4 protein levels by 
immunoblotting nuclear extracts from CMV-Luc-expressing 4T1 shNT and shATF4 cells, 
these cells were injected into the bloodstream of nude mice via the tail vein (Fig. 23A). 
Again, the formation of colonies was assessed by bioluminescent imaging of the mice. 
Unlike the HT1080 cells, where the colonies were localized to the lung area, the 4T1 
cells formed colonies throughout the abdomen, thorax, and head and neck areas of the 
mice (Fig. 23B). Also in contrast to the results garnered with the HT1080 cells, almost all 
of the mice injected with 4T1 shATF4 cells exhibited formation of colonies (Fig. 23B). 
There was a slight trend toward lower tumor burden (quantified as the total 
luminescence of the entire mouse) when ATF4 was knocked down, but this was not 
significant (Fig. 23C). Also, no significant difference was seen between the survival of 
the 4T1 shATF4 vs. shNT injected mice (Fig. 23D). There are several possible 
explanations for the disparate results between the 4T1 and the HT1080 cells, all of 
which will be explored in the discussion. 
 
Production of a cell line with doxycycline-inducible shATF4 expression. To more 
precisely recapitulate physiological metastasis, it was necessary to use a model where a 
primary tumor was established first and then subsequent metastasis could be monitored 
by imaging. Since we were unable to establish subcutaneous tumors with HT1080 
shATF4 cells, we generated HT1080 cells harboring CMV-Luc that also expressed 
doxycycline (dox)-inducible shATF4 (i-shATF4). This would allow us to turn off ATF4 
expression in the primary tumor after it had started to develop. Numerous clones were  
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Fig. 23. ATF4 expression does not affect tumor burden or survival of mice injected 
with 4T1 mammary carcinoma cells. A) 4T1 cells expressing CMV-Luc and either 
shNT or shATF4 were treated with DMSO or 0.5µM thapsigargin (- or + Tg, respectively) 
and nuclear extracts were immunoblotted for ATF4 expression. Ku80 was used as a 
loading control. B) Bioluminescent images of mice injected with 4T1 shNT or shATF4 
cells via the tail vein at 3 weeks after injection. Intensity scale applies to all mice. C) 
Average luciferase signal in the chest area of the mice injected in (B) plotted vs. time. 
Each line represents the average signal from 6 mice. D) Kaplan-Meier survival curves for 
mice intravenously injected with 4T1 shNT vs. shATF4 cells (n=6 for each cell type).  
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generated, and the efficiency of dox-induced ATF4 knockdown was evaluated by 
immunoblotting the nuclear lysates of thapsigargin-treated cells (Fig. 24A). As a control, 
HT1080 CMV-Luc cells with dox-inducible shNT (i-shNT) were also created and cloned. 
We then confirmed that four of the i-shATF4 clones with the best ATF4 knockdown were 
functional knockdowns by assessing the mRNA levels of two downstream targets of 
ATF4, CHOP and ATF3, after treatment with thapsigargin. As expected, the dox-treated 
i-shATF4 clones had a dampened response to thapsigargin treatment, with substantially 
reduced induction of ATF3 transcription as well as slightly diminished levels of CHOP 
(Fig. 24B,C). The functionality of ATF4 knockdown in these clones was also tested using 
an MTT assay. Previous work from our lab had shown that DLD1 human colorectal 
adenocarcinoma and HT1080 cells expressing shATF4 exhibited decreased viability 
when cultured without the addition of nonessential amino acids (NE aa’s) to the media 
(Ye et al, 2010). However, when we tried to replicate this using the i-shATF4 clones 
treated with dox, there was no difference in viability between cells grown with or without 
NE aa’s (Fig. 24D).  
 
Inducible ATF4 knockdown increases tumor doubling time. To ascertain the effect 
of inducing shATF4 in established tumors, HT1080 i-shNT cl.1 or i-shATF4 cl.4 cells 
were injected subcutaneously into the flanks of nude mice (one flank per mouse). After 
17 days, mice were divided into two groups, and half were given dox dissolved in their 
drinking water. The time to appearance of a palpable tumor varied greatly among the 
mice, regardless of the cell type or treatment, ranging from a few weeks to almost two 
months (Fig. 25A,B). There was, however, a significant difference in the tumor doubling 
time (measured using calipers) of the untreated and dox-treated i-shATF4 tumors, with 
tumors with induced expression of shATF4 having almost twice the doubling time of  
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Fig. 24. Generation of inducible shATF4-expressing cells. A) HT1080 inducible 
shATF4 (i-shATF4) clone 4, as well as the inducible shNT (i-shNT) clone 1, were dosed 
with doxycycline (Dox) for 48h prior to treatment with DMSO or 0.5µM thapsigargin, and 
the efficiency of ATF4 knockdown was analyzed by immunoblotting nuclear lysates for 
ATF4 expression. Ku80 expression was used as a loading control. B-C) mRNA from four 
of the most efficient i-shATF4 clones and one of the i-shNT clones, after 48h of dox and 
then 6h of 200nM Tg with dox, was analyzed by qPCR for CHOP (B) and ATF3 (C). 
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(Fig. 24 continued) 
Values were normalized to the amount of 18s rRNA. Bars signify the average of three 
technical replicates. Representative graphs from one of two experiments are shown. D) 
The viability of dox-treated HT1080 i-shNT and two clones of i-shATF4 cells when 
cultured with and without nonessential amino acids (NE aa’s) was assessed with an 
MTT assay. Cells were pretreated with dox for 48h prior to plating for the MTT, and fresh 
dox was added every two day during the assay. MTT staining was performed 6 days 
after treating cells with or without NE aa’s. Data presented as the mean ± SEM (n=6). A 
representative graph from one of two separate experiments is shown. 
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Fig. 25. Induced shATF4 expression extends tumor doubling time. A-B) Tumor 
growth curves of HT1080 i-shNT (B) or i-shATF4 (A) cells implanted subcutaneously into 
mice. At day 17, half of the mice were started on dox treatment (6 with i-shATF4 tumors 
and 2 with i-shNT tumors). Each line represents the volume of a single tumor vs. time. 
C) Scatter plot showing the individual tumor doubling times (one point was excluded 
from the i-shATF4 +Dox group because of injection irregularities). The mean and SEM 
for each group is also shown. * p=0.0404 by the student’s t-test.  
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uninduced tumors (Fig. 25C). Note that one of the i-shATF4 dox-treated tumors was 
excluded from this analysis because, during the injection, some of the tumor cells went 
across the mouse’s back and onto the opposite flank. Since we did not see as strong of 
a phenotype as expected when the HT1080 i-shATF4 tumors were treated with dox, we 
investigated whether the dox was actually reaching the tumor. Because turboRFP was 
coexpressed with the shRNA upon the addition of dox, we examined tumor sections via 
microscopy for RFP expression and confirmed that dox was indeed reaching the entire 
tumor (Fig. 26A). Nevertheless, there was no corresponding decrease of ATF4 
expression in the i-shATF4 tumors that were treated with dox (Fig. 26B).  
 
Impact of inducible shATF4 expression on metastasis. Finally, we utilized an 
orthotopic xenograft tumor model to explore whether ATF4 plays a role in tumor 
metastasis. Nude mice were again injected with HT1080 CMV-Luc i-shNT or i-shATF4 
cells, but this time the cells were implanted into one thigh muscle of each mouse. Half of 
the mice were started on dox treatment 11 days after tumor cell injection, which was 
before the tumors were palpable but after bioluminescent signal was clearly visible in the 
legs of most mice. Unexpectedly, we observed higher signal in the primary i-shATF4 
tumors of mice treated with dox than in those that did not receive dox (Fig. 27A). After 
three weeks, we began imaging the lungs and upper bodies of the mice to look for signal 
from micrometastases. Due to complications with signal reflecting from the primary 
tumor, only data from the last few time points are shown. At these later time points, a 
difference did emerge between the average signal in the chest/lung area between 
untreated mice and mice given dox. Specifically, the signal in the lung area of i-shATF4-
implanted mice given dox was lower than in those that were not maintained on dox, 
although the difference was not significant (p = 0.1334 by student’s t-test) (Fig. 27B).  
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Fig. 26. Doxycycline infiltrates flank tumors but does not reduce ATF4 expression. 
A) Phase contrast and red fluorescent microscopy images of sections from i-shATF4 
flank tumors from an untreated and two different dox-treated mice. Original objective 
used was 10x. B) ATF4 expression in all tumors was determined by immunoblotting 
homogenized tumor lysates. Levels of p-eIF2α and eIF2α were also analyzed. Ku80 was 
used as a loading control. 
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Fig. 27. Induced shATF4 has a minimal effect on metastasis. A) Average primary 
tumor luminescence for mice injected into the thigh muscle with either i-shNT or i-
shATF4 HT1080 cells and then treated with or without dox (starting on day 11). The i-
shATF4 -Dox, i-shATF4 +Dox, i-shNT -Dox, and i-shNT +Dox lines represent mean and 
SEM of 8, 7, 2, and 3 mice, respectively. B-C) The bioluminescent signal in the chest 
area (B) or combined head and chest area (C) of mice implanted with HT1080 i-shATF4 
cells in the thigh muscle was stratified by whether or not the mice received dox and then 
plotted. The i-shATF4 -Dox line represents an average of 8 mice and the i-shATF4 +Dox 
an average of 7. Also shown is the SEM for each point.  
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Some signal was also observed in the head and throat area of some mice, which could 
have been metastases in the lymph nodes, so the average radiance of the entire chest 
and head of each mouse was also analyzed. These results mimic the trend of the signal 
seen in the lungs, with a small divergence in the curves at 45 days (Fig. 27C). Again, 
this difference was not statistically significant (p = 0.1576 by student’s t-test).  
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B. Materials and Methods 
Chemicals 
Fibronectin was acquired from BD Biosciences (San Jose, CA). Sucrose was bought 
from Fisher Scientific (Hanover Park, IL). Thapsigargin, puromycin, and doxycycline 
were purchased from Sigma-Aldrich (St. Louis, MO). All cell culture reagents were from 
Gibco (Grand Island, NY), except β-mercaptoethanol, which was purchased from 
Millipore (Billerica, MA). 
 
Cell culture and generation of stable cell lines 
HT1080 human fibrosarcoma cells were obtained from ATCC (Manassas, VA), and 4T1 
mouse mammary carcinoma cells were a gift from Dr. Steve Albelda (University of 
Pennsylvania, Philadelphia, PA). These cells were cultured in Dulbecco's modified Eagle 
medium (DMEM) supplemented with penicillin, streptomycin, and 10% fetal bovine 
serum (FBS). For bioluminescent imaging, cells were transfected with a constitutively 
expressed luciferase plasmid (CMV-Luc; from Genlantis, San Diego, CA) using 
Lipofectamine2000 (Invitrogen, Grand Island, NY) and then selected with 500µg/ml 
G418. 4T1 cells with stable non-targeting shRNA or knockdown of ATF4 were 
established by transfection of pSM2-shNT (Thermo Scientific, Waltham, MA) or pLKO-
shATF4 (Sigma-Aldrich) plasmids, respectively, with Lipofectamine2000 and selected 
with puromycin (4µg/ml and reduced to 0.5 µg/ml for maintenance). Tetracycline-
inducible shNT and shATF4 (i-shNT and i-shATF4) HT1080 cells were created by 
transfecting cells with TRIPZ shNT or shATF4 (Thermo Scientific), selecting with 2µg/ml 
puromycin and maintaining them in 0.25µg/ml puromycin. Pretreatment with doxycycline 
(1µg/ml) for 48h was used to induce the expression of the shRNAs in all experiments. 
Anytime an experiment lasted longer than 2 days, the media was changed and fresh 
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doxycycline was added at 48h intervals. HT1080 shATF4 and i-shATF4, as well as 4T1 
shATF4 cells, were grown in media supplemented with non-essential amino acids (NE 
aa’s) and 55µM β-mercaptoethanol.  
 
Immunoblot analysis 
Immunoblotting was performed as previously described (Koumenis et al, 2002), with the 
exception that proteins were transferred to polyvinylidene fluoride membranes. Protein 
concentration was determined using Pierce® 660 nm Protein Assay Reagent (Thermo 
Scientific, Waltham, MA), according to the manufacturer’s instructions. Primary 
antibodies for the following proteins were used: ATF4 (Santa Cruz Biotechnology, Santa 
Cruz, CA), Ku80, p-eIF2α, and eIF2α (all from Cell Signaling Technology, Danvers, MA).  
 
Luciferase assay 
Cells were seeded in a 6-well plate and incubated overnight. Luciferase activity was 
quantified using the Luciferase Assay System from Promega (Madison, WI). Each 
sample was read in triplicate in a white Microfluor-1 96-plate (Thermo). 
 
Real-time quantitative PCR 
RNA was isolated with TRIzol® Reagent (Ambion, Carlsbad, CA) by following the 
protocol provided with it. Reverse transcription was performed using AMV Reverse 
Transcriptase (Promega). Real-time quantitative PCR was done using Power SYBR® 
Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and was analyzed with the 
Applied Biosystems 7300 Real-Time PCR System. PCR primers were purchased from 
Invitrogen. Relative mRNA levels were quantified using the standard curve method. The 
following primers were used: human 18S rRNA-F: 5’-CAATTACAGGGCCTCGAAAG, 
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and 18S rRNA-R: 5’-AAACGGCTACCACATCCAAG; human ATF3-F: 5’-
TAGGCTGGAAGAGCCAAAGA, and  
ATF3-R: 5’-TTCTCACAGCTGCAAACACC; and human CHOP-F: 5’-
GCGCATGAAGGAGAAAGAAC, and CHOP-R: 5’-CCAATTGTTCATGCTTGGTG. 
 
Cell viability assay 
Cell viability was analyzed using the Cell Proliferation Kit I (MTT assay) (Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s protocol. Briefly, cells 
were seeded at low density in 24-well plates, and the following day, media with or 
without NE aa’s was added. Once the cells supplemented with NE aa’s reached 
confluence, the MTT assay was started. Each well was read in triplicate in a 96-well 
plate at absorbances of 550 and 690nm. 
 
Scratch assay 
The procedure used was based on a protocol published  by Liang and colleagues (Liang 
et al, 2007). Briefly, cells were seeded onto 6-well plates that had previously been 
coated with fibronectin (10µg/ml for 2h at 37°C). Once cells were confluent, mo st of the 
media was aspirated and two scratches per well were made using a p10 pipet tip (lines 
were etched onto the underside of the 6-well plate to use as location references for each 
scratch). The wells were washed with media to remove debris, and then phase images 
of each scratch using the 10x objective were immediately captured on a Nikon Eclipse 
TE2000-U (Tokyo, Japan) with Image-Pro Plus 6.0 software (MediaCybernetics, 
Rockville, MD). Images were taken every 2h at the reference etching until the scratches 
were closed. To analyze the migration, the area of the open scratch (not covered by 
cells) was determined for each time point using ImageJ software (National Institutes of 
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Health, Bethesda, MD). The scratch area at each time was subtracted from the original 
scratch area to determine the change in area covered by the cells with time.  
 
Transwell migration assay 
BD Falcon™ FluoroBlok™ individual transwell cell culture inserts with an 8µm pore size 
were used for this assay. Cells were seeded into the upper wells in media without FBS. 
Media with 10% FBS was added to the lower chamber as the chemoattractant. 
Transwell plates were incubated at 37°C for the ind icated length of time, and then 
migrated cells were fixed with methanol and stained with DAPI (a gift from Dr. Theresa 
Busch’s lab). For each well, the 20x objective of the Nikon Eclipse TE2000-U and 
Image-Pro Plus 6.0 software were used to take six random images of the migrated cells. 
The number of nuclei in each image was counted and the total number of cells from all 
six images was determined for each well.  
 
Hypoxia treatments 
Cells were subjected to hypoxia using the InVivo2 400® (Russkin Technologies, 
Bridgend, UK) chamber.  
 
Animals 
Female athymic nude mice (Nu/Nu) from Charles River Laboratories (Wilmington, MA) 
were used for all in vivo experiments. For experiments using the inducible HT1080 cells, 
animals were given doxycycline in their drinking water at a concentration of 1mg/ml. In 
addition, drinking water for both untreated and dox-treated mice was supplemented with 
5% sucrose.  
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Flank tumors: Mice were subcutaneously injected into one flank with 1 x 106 cells in 
200µl phosphate-buffered saline (PBS). Tumors were monitored 3 to 4 times a week and 
dimensions were obtained with digital calipers (Marathon Management Company, 
Richmond Hill, Canada). Tumor volume was calculated using the formula: V = (width2 x 
length)/2, where length was always the longest dimension. Mice were euthanized when 
either the tumor volume exceeded 800mm3, the animal had lost >15% of its body weight 
or the tumor had ulcerated. Tumors were excised and half was embedded in Tissue-Tek 
OCT (Sakura, The Netherlands) and the other half was cut into smaller pieces, which 
were individually snap frozen with liquid N2. The tumor doubling rate was calculated 
using the equation: DT = (t2 – t1)ln2/ln(V2/V1) (Mehrara et al, 2007). 
Lung colonization assay: HT1080 cells (5 x 105) or 4T1 cells (2 x 105) were resuspended 
in a total volume of 100µl PBS and injected into the tail veins of mice. Mice were imaged 
weekly for lung colony formation. Animals were euthanized when they had lost >15% of 
their body weight. 
Intramuscular tumors: Cells (5 x 105) suspended in 30µl PBS were injected into one 
thigh muscle of each mouse. Mice were imaged 1 to 2 times a week to monitor the 
primary tumor growth as well as the development of lung metastases. When an animal 
had either lost >15% of its body weight, or the primary tumor became cumbersome and 
inhibited movement, or the primary tumor ulcerated, the mouse was euthanized. The 
primary tumor was removed, and half was embedded in OCT and the other half was cut 
into pieces that were snap frozen.  
 
Bioluminescent imaging 
Prior to imaging, mice were anesthetized and injected with 200µl of 50µg/ml D-luciferin 
(Regis Technologies, Morton Grove, IL). Mice were then optically imaged with up to 5 
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min exposures using the Carestream imager (Carestream Health Inc., Rochester, NY), 
the IVIS Lumina II or the IVIS Spectrum (PerkinElmer, Waltham, MA). Tumor 
size/burden was determined by quantifying the average relative light intensity of the 
chest/lung area, chest and head area, or the primary tumor site using either Carestream 
Molecular Imaging software (Carestream Health Inc.) or Living Image® software 
(PerkinElmer). 
 
Tumor sectioning 
Tumors embedded in OCT were sectioned into 14µm slices with a HM 505N Cryostat 
Microtome from Microm International (Walldorf, Germany) and placed onto slides. 
 
Graphing and statistics 
All graphs were generated and all statistics (student’s t-test and log-rank test – specified 
in figure legends) were performed with GraphPad Prism software (GraphPad Software, 
Inc., La Jolla, CA).  
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Chapter IV: Discussion 
A. Characterization of the ATF4 modulator E235 
It has been previously demonstrated that inhibition of the ISR pathway, whether by 
inhibiting PERK activity, eIF2α phosphorylation, or ATF4 expression, sensitizes cells to 
ER stress (Harding et al, 2000b; Scheuner et al, 2001; Ye et al, 2010). This sensitization 
is due to the accumulation of unfolded proteins in the ER and results in an increase in 
the levels of apoptosis (Koumenis, 2006). However, a key aspect of the ISR is that under 
certain biological contexts (e.g., hyperactivation by pharmacological agents, prolonged 
activation, etc.), it can also lead to cytotoxicity. With sustained activation of the ISR, cells 
can undergo permanent cell growth arrest by PERK-dependent inhibition of cyclin D1 
(Brewer & Diehl, 2000). Alternatively, overactivation of the ISR can lead to cell death due 
to inhibition of protein synthesis and/or ATF4-mediated induction of the pro-apoptotic 
protein CHOP (Friedman, 1996; Harding et al, 2000a; Harding et al, 2000b). Our group 
has previously shown that hypoxia, a physiological activator of ER stress, increases the 
sensitivity of HeLa cells to the ER-stress inducing agents thapsigargin and bortezomib 
(Fels et al, 2008).  
 
In this manuscript, we describe the identification of a novel, potent activator of cellular 
senescence, E235. The ISR and the UPR are increasingly being recognized as 
attractive targets for antitumor agents.  Our screen was not able to identify any effective 
inhibitors of the PERK-eIF2α-ATF4 arm of the ISR. This may have been because the 
number of compounds screened was moderate (65,000), compared to larger, more 
encompassing chemical libraries. It is possible that screening of additional libraries may 
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reveal specific inhibitors of this pathway.  No specific inhibitors of this pathway have yet 
been reported in the literature. 
 
We did, however, identify a potent activator of ATF4 expression with our screening 
assay.  This compound, E235, was active at high nM to low µM concentrations in 
inducing upregulation of ATF4-Luc activity and ATF4 protein expression in a variety of 
human and mouse transformed cells.  Intriguingly, E235 was unable to induce robust 
upregulation of eIF2α phosphorylation or ATF4 expression in untransformed human 
diploid fibroblasts.  This finding suggests that the mechanism of ISR activation by E235 
is tumor cell-specific, although we were unable to definitively determine which ISR 
kinase was being activated by E235.  Moreover, E235 displayed potent anti-proliferative 
activity against transformed cell lines without causing significant apoptosis.  Rather, 
careful analysis of the effects of E235 using time-lapse microscopy revealed that it 
induced cellular senescence. This effect extended to the normal human fibroblasts.  
However, since normal tissues are not rapidly proliferating in vivo, and given the lack of 
any direct cytotoxicity by E235, we believe that in vivo this agent should display low 
toxicity towards normal tissues.   
 
One caveat that must be considered is the fact that senescent cells can both suppress 
and promote tumor formation (Rodier & Campisi, 2011). Traditionally, senescence is 
considered to be anti-tumorigenic, as it suppresses two of the major hallmarks of cancer 
cells: expanded growth potential and the ability to continue proliferation in the presence 
of activated oncogenes (Hanahan & Weinberg, 2000). The results of several studies 
support this, demonstrating that senescent cells are commonly present in premalignant 
lesions but decrease in frequency in malignant tumors (Bartkova et al, 2005; Braig et al, 
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2005; Chen et al, 2005; Collado et al, 2005; Michaloglou et al, 2005). On the other hand, 
senescent cells have been shown to secrete many factors that promote tumor 
progression, such as interleukin-6 and -8 and matrix metalloproteases, which can 
stimulate basement membrane invasion, and vascular endothelial growth factor A and 
growth-related oncogene α, angiogenesis-inducing factors (Coppé et al, 2006; Coppé et 
al, 2010; Coppé et al, 2008; Kang et al, 2003; Ksiazek et al, 2008; Millis et al, 1992). 
These findings are reinforced by the fact that co-injection of premalignant epithelial cells 
that are not normally tumorigenic with senescent fibroblasts promotes cancer formation 
in vivo (Krtolica et al, 2001). Therefore, studies will need to be performed to ensure that 
E235 does not promote the progression of premalignant lesions in vivo.  
 
Mechanistically, E235 primarily induced a cell cycle arrest at the G2/M checkpoint.  This 
was accompanied by potent activation of DNA damage signaling, as evidenced by 
increased phospho-p53 (Ser15), Chk2, and γ-H2AX in transformed cells.  Notably, DNA 
damage signaling was significantly attenuated in normal human fibroblasts, with 
marginal induction of these markers.  Moreover, this activation of the G2/M checkpoint 
and DNA damage signaling was not accompanied by any significant increase in physical 
DNA damage, since we failed to observe any increase in DNA tail moment by the 
sensitive COMET assay.  In contrast, a single dose of 4Gy elicited a substantial increase 
in tail moment in the same cells.  Collectively, our results indicate that E235 causes 
cellular senescence by inducing DNA damage signaling in actively dividing transformed 
cells but not in normal fibroblasts.  Although we also observed a strong induction of the 
CDKI, p21, by E235, this increase was not necessary for the induction of senescence, 
since E235 induced similar levels of senescence in p21-deficient and p21-proficient 
MFs.  However, B16F10 cells with knocked down p21 expression exhibited lower overall 
81 
 
viability, indicating that p21-mediated cell cycle arrest must play a small, but significant, 
cytoprotective role. 
 
Despite a robust upregulation of ATF4 translation by E235, the induction of senescence 
was not dependent on ATF4, as both HT1080 shATF4 cells and ATF4 -/- MFs senesced 
when treated with low doses of E235. In addition, decreased expression of ATF4 did not 
significantly alter the cell cycle distribution of cells treated with 1µM E235 (data not 
shown). However, abrogation of ATF4 expression did lead to decreased levels of DNA 
damage signaling (γ-H2AX). This might provide a potential explanation for the increased 
sensitivity of shATF4 cells to E235, as the induction of DNA damage signaling could 
allow cells to ameliorate the stress induced by E235. Also, as we have shown that 
shP21 cells are more sensitive to E235, p21 upregulation by DNA damage signaling 
may contribute to the cytoprotective role of ATF4. Hence, the increase in clonogenic cell 
death in ATF4 knockdown cells could be attributed to a decrease in DNA damage 
signaling, resulting in reduced p21 induction (Fig. 28). Additional studies will be essential 
to confirm this and to further elucidate the effects of E235-mediated ATF4 induction on 
overall survival. 
 
Although we have eliminated several potential mechanisms for induction of senescence 
by E235, such as induction of p21 or ATF4, inhibition of Aurora kinases or 
topoisomerases, and induction of ROS, we still do not know exactly how E235 elicits its 
pro-senescence effects.  It is possible that it may affect the process of DNA replication 
without inducing DNA damage or it could be a histone deacetylase inhibitor.  A panel of 
over 400 known kinases was screened to determine if E235 exhibited inhibitory activity 
against any specific kinases (KINOMEscan, a division of DiscoveRx, San Diego, CA)  
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 28. Proposed mechanism of action of E235. Schematic depicting the possible 
connection between levels of ATF4 expression and subsequent clonogenic cell death. 
Also included is ATF4-independent senescence. 
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(results not shown), but it did not reveal any significant activity against any kinase known 
to be involved in cell cycle regulation.  We are in the process of investigating further the 
mechanism by which E235 induces senescence. 
 
In summary, our results show that E235 induces ATF4 expression and establish a link 
between increased expression of ATF4 and the induction of DNA damage signaling. 
Further studies will need to be conducted to elucidate the mechanism by which E235 
stimulates ATF4 expression and to determine the connection between ATF4 
upregulation and the induction DNA damage signaling. Also, based on these promising 
in vitro results, we plan to begin studies in mice. The maximum tolerated dose of E235 
and the effects of E235 on the growth of subcutaneous tumors will be examined. 
 
B. Role of ATF4 in metastasis 
Metastasis is a multi-stage process consisting of migration and invasion, intravasation, 
circulation, extravasation, and colonization of a secondary site. During the progression of 
metastasis, tumor cells are repeatedly selected for their ability undergo – and survive the 
stresses of – each step (Valastyan & Weinberg, 2011). Because ATF4 regulates a gene 
transcription program designed to cope with hypoxia and nutrient deprivation, both of 
which can drive metastasis, we hypothesized that ATF4 expression facilitates tumor cell 
metastasis. Therefore, we predicted that ablating ATF4 would reduce the metastatic 
potential of cancer cells. 
 
ATF4 and tumor cell migration 
We first investigated if ATF4 expression could influence the migratory capacity of tumor 
cells. Using a scratch assay, or wound healing assay, we showed that depletion of ATF4 
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did not affect the motility of HT1080 cells under normoxia. This was corroborated with a 
transwell migration assay, which demonstrated again that knocking down ATF4 
expression did not alter the migration of HT1080 cells, this time under hypoxia. Our 
results contradict those from a recent study that illustrated that knockdown of ATF4 
decreased the migration of cells under hypoxia (Nagelkerke et al, 2013). The differential 
findings may be a consequence of the cell type utilized – we used fibrosarcoma cells 
while they performed their studies with a breast cancer line.  
 
ATF4 and tumor cell lung colonization: HT1080 cells 
Also in this study, in three separate experiments, we demonstrated that knocking down 
ATF4 in HT1080 fibrosarcoma cells completely prevented lung colonization by these 
cells when injected into the tail veins of mice. In fact, while almost all of the mice injected 
with HT1080 cells expressing nontargeting shRNA demonstrated lung colonization and 
subsequent mortality, not a single mouse injected with either HT1080 shATF4 clone 
developed lung colonies. Indeed, HT1080 shATF4-injected mice were still alive and 
healthy over three months after inoculation. While we realize that this is not a complete 
metastasis model, it does suggest that ATF4 is required for the execution of one or more 
of the later stages of metastasis, i.e. surviving circulation, extravasation, and/or 
colonization and proliferation within the lung.  
 
Supporting this, recent experiments (all unpublished data) by a colleague in the lab, Dr. 
Souvik Dey, provide evidence that ATF4 may be indispensable for surviving the 
circulation during metastasis. He has shown that while HT1080 cells grown in 
suspension activate the ISR, cellular detachment results in very little anoikis. 
Furthermore, his data suggest that ATF4 plays a crucial role in the resistance to anoikis 
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in HT1080 cells. When HT1080 shATF4 cells were grown in suspension, high levels of 
cleaved PARP and cleaved caspase-3 accrued. This was supported by MTT assay 
results that show reduced viability of HT1080 ATF4 knockdown cells when grown in 
suspension as compared to the shNT cells. We hypothesized that genes induced by 
ATF4 protect the cell from the stresses associated with anoikis, including the generation 
of ROS and upregulation of autophagy. Indeed, treatment with the autophagy inhibitor 
Spautin-1 had the same effect on cleavage of PARP and cell viability as the ablation of 
ATF4 did; however, it is important to note that he has not yet shown a direct link 
between ATF4 and autophagy. He has also established that treating detached HT1080 
shATF4 cells with antioxidants (either N-acetylcysteine or Trolox) substantially 
diminishes both PARP and caspase-3 cleavage and that these compounds rescue the 
resistance to anoikis seen in wildtype ATF4 cells. Together, these results suggest that 
knocking down ATF4 prevents lung colonization by sensitizing circulating tumor cells to 
anoikis (Fig. 29).  
 
ATF4 and tumor cell lung colonization: 4T1 cells 
Disappointingly, despite the dramatic effect of knocking down ATF4 expression on 
HT1080 lung colonization, these results could not be replicated with 4T1 murine 
mammary carcinoma cells. In this model system, there was very little, if any, impact of 
ATF4 status on the ability of 4T1 cells to colonize foreign sites in the mouse. Both 4T1 
shNT and shATF4 cells were able to colonize the lungs, as well as numerous other sites 
within the abdominal, thoracic, and head and neck areas. However, we did observe a 
trend toward decreased overall bioluminescent signal in mice injected with 4T1 shATF4 
cells, but it was not statistically significant. Although these data did not corroborate the 
experiments with the HT1080 cells, there are a few possible explanations for the  
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Fig. 29. ATF4 and its role in metastasis. ATF4 may support metastasis of 
fibrosarcoma by protecting the circulating tumor cells from anoikis. It may also have a 
role in tumor cell extravasation or colonization of the secondary site. 
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differential results. First, the effect of ATF4 expression could be dependent upon the 
tumor cell type. HT1080 cells arose from fibroblasts, so they are undifferentiated and of 
mesenchymal origin (Rasheed et al, 1974). In contrast, 4T1 cells are epithelial, as they 
were derived from a mammary tumor (Aslakson & Miller, 1992). As explained previously, 
epithelial and mesenchymal cells are vastly different in their cell-cell adhesion properties 
and in their migratory ability. Another, more obvious, difference between these two cell 
lines is that one was derived from a human tumor while the other originated from a 
mouse tumor. It is possible that human cancer cells, compared to mouse tumor cells, are 
more dependent upon ATF4 and the ISR during the metastatic process. 4T1 cells are 
considered to be a very aggressive tumor line, so it is also possible that less aggressive 
tumor cells rely more heavily on ATF4 expression or that 4T1 cells have been selected 
for upregulation of a pathway that has overlapping functions with the ISR.  
 
HT1080 inducible shATF4 cells: flank tumors 
Because the 4T1 lung colonization experiment did not show a strong effect of ATF4 
knockdown, we decided to continue our studies using the HT1080 cells. However, to 
fully mimic the physiological process of metastasis, we needed a model where the 
expression of ATF4 could be turned off after the primary tumor had established. To do 
this, we generated HT1080 cells that stably expressed a tetracycline (doxycycline)-
inducible shRNA against ATF4. Previous work from our lab demonstrated that knocking 
down ATF4 in HT1080 cells decreased xenograft tumor volume and growth rate, so we 
first tried to duplicate these results using the i-shATF4 cells (Ye et al, 2010). We also 
utilized inducible shNT cells as a control to ensure that dox alone did not influence tumor 
growth. We saw no trend in the time to tumor onset based on cell type injected (i-shNT 
or i-shATF4) or whether or not mice were treated with dox. Nevertheless, treating i-
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shATF4 tumors with dox and inducing ATF4 expression did decrease the tumor growth 
rate, as evidenced by the significantly higher tumor doubling time in these mice.  
 
Since the effect on tumor growth with ATF4 knockdown was not as strong as that 
observed in the prior study by Ye et al, we investigated whether the inducible shATF4 
construct was working in vivo. We verified that the dox was able to permeate the tumor 
by confirming that RFP was expressed throughout the tumors. On the other hand, we 
found that the i-shATF4 tumors from mice treated with dox still had ATF4 expression. 
However, levels of ATF4 were not analyzed until the very end of the experiment, so the 
expression would only be representative of tumor cells that had withstood survival 
selection. This may explain why the tumor doubling time was significantly increased in 
the induced i-shATF4 tumors. It is possible that cells with decreased ATF4 levels were 
eliminated from the forming tumors as the tumors became hypoxic or nutrient-deprived. 
Then, by selective pressure, cells with reduced capability to repress ATF4 were selected 
for and eventually populated the tumor. In the future, we will repeat this experiment but 
assay for ATF4 levels a few days after beginning doxycycline treatment.  
 
HT1080 inducible shATF4 cells: intramuscular injections and metastasis 
We also used the HT1080 inducible cells in a complete metastasis model by implanting 
them into the thigh muscles of mice, a pseudo-native environment for fibrosarcoma cells. 
Unexpectedly, the bioluminescent signal in the primary i-shATF4 tumors was actually 
higher in dox-treated mice compared to untreated mice. However, signal does not 
always directly correlate to tumor size, since necrotic tissue does not luminesce and 
larger tumors often have more necrotic areas (De Jaeger et al, 1998; Milross et al, 
1997). Consequently, the higher luciferase activity seen in the dox-treated vs. untreated 
89 
 
i-shATF4 tumors could be explained if the dox-treated tumors had fewer areas of 
necrosis. Importantly, at the last time point that both i-shATF4 groups were imaged, we 
observed that the signal in the lungs of untreated mice was more than twice that seen in 
the dox-treated mice, although the difference was not significant An identical trend was 
seen when the average signal of the chest and head regions were combined. While we 
do not know if these trends would have continued, they do suggest that inducing ATF4 
knockdown may impair the metastasis of fibrosarcoma cells. This experiment should be 
repeated with surgical resection or irradiation of the primary tumor to allow us to monitor 
the metastasis to the lungs without the primary tumor being a limiting factor. Similar 
approaches have been used in transgenic tumor models of fibrosarcoma, where leg 
amputation was necessary to observe metastases in the lungs of these mice (Kirsch et 
al, 2007). 
 
Ongoing experiments 
Several experiments related to these studies are currently underway. For instance, we 
have injected the HT1080 i-shATF4 cells intravenously into mice and then induced 
shATF4 expression the following day. We reasoned that if ATF4 is in fact protecting cells 
from anoikis, the difference between induced and uninduced i-shATF4 HT1080 cells 
may be more evident if we look specifically at the second half of the metastatic cascade. 
In another study, HT1080 cells that express constitutive shNT or shATF4 have implanted 
into the thigh muscles of a small group of mice. We postulated that if shATF4 cells were 
to be seeded in a less hostile environment than the oxygen- and nutrient-destitute 
subcutaneous one, they may be able to survive and form a primary tumor. At two weeks 
post-injection, mice implanted with HT1080 shATF4 cells still have luminescent signal in 
their legs, indicating that primary tumors had indeed developed. We will continue to 
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monitor these mice for the appearance of lung metastases. Also, a potential role for 
ATF4 in invasion through the ECM is being further investigated. We plan to evaluate the 
invasive potential of the HT1080 shNT and shATF4 cells, under either normoxia or 
hypoxia, with a transwell invasion assay. 
 
In summary, we have demonstrated that ATF4 expression is necessary for murine lung 
colonization by HT1080 cells. We have also shown that inducing ATF4 knockdown may 
decrease the metastasis of HT1080 cells from a primary site. Data from the lab suggest 
that these effects could be due to ATF4-mediated protection of tumor cells from anoikis 
while in circulation (Fig. 29). However, further experiments are needed to confirm the 
effect of ATF4 expression on metastasis. Additional studies will also be required to 
determine if this effect holds true for other tumor types.  
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